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What is the dual prevention pill (DPP)?
• The DPP is a single daily capsule
to prevent HIV and unintended
pregnancy.
• Each DPP capsule contains
2 tablets: Truvada for
oral pre-exposure
prophylaxis (PrEP)
and Zinnia F, an oral
contraceptive pill (OC) for pregnancy
prevention. Each OC tablet contains
ethinyl estradiol 30mcg/levonorgestrel
150mcg.

What does the DPP look like?
Who can take
the DPP?
The DPP is for
women who are
not pregnant, are
HIV-negative, and
who feel they are at
risk of getting HIV.

• The DPP comes in a box with a 28-day
supply of capsules.
• Each box contains 4 pouches, 1 for each
week in the month.
• Each pouch contains a blister strip of 7
capsules.
• Pouches 1–3 have 21 pink and white
DPP capsules (PrEP+OC) to use on Days
1–21.
• Pouch 4 has 7 white capsules with PrEP
only to be used on Days 22–28.

• Each PrEP tablet contains 2 drugs: 200
mg emtricitabine (FTC) and 300 mg
tenofovir disoproxil fumarate (TDF).
• The DPP regimen contains 21 DPP
capsules and 7 capsules with Truvada
only.

How do I take the DPP?

What if I miss a dose of the DPP?

• Take one capsule per day
at the same time each
day.

• If you miss a taking a capsule—whether
it is a pink and white DPP capsule or a
white PrEP capsule—take it as soon as
you remember, even if it means taking 2
capsules in one day (in a 24-hour period).
Then, continue taking the DPP once daily.

• Set an alarm to remind
yourself to take the tablet
or find any method that
would help you not to
miss a dose.

Pill
Time

• Use the pouches in order,
starting with Pouch #1.
• Take the capsules in order, starting with
Capsule #1.
• Do not open a pouch until you are ready
to take the first capsule in that pouch.

• Do not take more than 2 capsules in a
day.
• Any missed capsules can increase
your risk of getting HIV and unintended
pregnancy.
• If you miss 2 or more doses of the DPP,
one after the other, call the study staff
right away; use a back-up (condoms) until
you can go to the study clinic.

Do I need to use condoms when using
the DPP?
• It takes 7 days for the DPP to start
working to prevent HIV and pregnancy.
So, either abstain from sex or use a
condom until you have been using the
DPP for at least 7 days.
• The DPP does not prevent STIs, so we
recommend using condoms to prevent
STIs.
• Male and female
condoms will be
available in the study
clinic.

How do I store the DPP?
• The DPP should be
stored below 30°C
(in a cool, dry
place), away from
sunlight.

C

30˚

• The pouches do not
need to be kept in the
box; if it is easier to store
the pouches separately, you
may do that. But remember
to use the pouches in order of
the numbers on the pouch (1, 2,
3, 4).
• After opening the pouch, you can take
out the blister strip and carry it with you.
• Bring all leftover DPP capsules (including
any missed doses) to your next study
clinic visit.

What side effects should I expect?

When should I go to the clinic?

What should I do if I have severe side effects?

Most common side
effects expected
(from PrEP and OC
components) are:

Come to the study clinic if you have any of
these symptoms:

Severe side effects are extremely rare. Get emergency
medical care if you experience any of the following:

• Vomiting, nausea, or diarrhea that
persists for more than 48 hours

• Unusual pain or swelling in the leg

Headache, nausea,
breakthrough bleeding/
spotting, breast
tenderness, abdominal
pain, bloating, weight
decrease, dark spots on
skin

• Unusual vaginal spotting or bleeding (not
related to menses)
• Sudden skin rash

• Chest pain which may spread into the left arm
• Unusual, persistent, severe headaches
• Sudden difficulty breathing
• Coughing up blood
• Sudden partial or complete loss of
vision, seeing double, or dizziness
• Sudden weakness/numbness on
1 side of body/1 part of body
• Problems with movement
• Severe abdominal pain

What medications are not allowed when using the DPP?

Who do I call if I have a problem?

While taking the DPP, do not use:

Dr Nkosiphile Ndlovu
Wits RHI
7 Esselen Street, Hillbrow
Johannesburg
+27 11 358 5471
+27 84 722 5877

• Any birth control methods with hormones, other than the ones provided in the study
(such as Triphasil or Nordette [Levonogestrel/Oestrogen] and Depo-Provera
[Medoxyprogestrone])
• Use of any HIV medications (such as Tenofovir, Lamivudine, Efavirenz and Lopinavir/
Ritonavir)
• Rifampicin
• Rifabutin
• Any antiepileptics (such as Lamotrigine, Sodium
Valproate and Valproic Acid)
• Hepatitis C treatments (Ledipasvir/sofosbuvir)
You can use other prescription or over-the-counter
medications.

OR
Visit the clinic
between 08:00
and 16:30 weekdays
Research Centre
Contact Number:
+27 67 072 7010

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use
TRUVADA safely and effectively. See full prescribing information
for TRUVADA.
TRUVADA® (emtricitabine and tenofovir disoproxil fumarate)
tablets, for oral use
Initial U.S. Approval: 2004
WARNING: POSTTREATMENT ACUTE EXACERBATION OF
HEPATITIS B and RISK OF DRUG RESISTANCE WITH USE OF
TRUVADA FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP)
IN UNDIAGNOSED EARLY HIV-1 INFECTION
See full prescribing information for complete boxed warning.
• Severe acute exacerbations of hepatitis B (HBV) have been
reported in HBV-infected individuals who have
discontinued TRUVADA. Hepatic function should be
monitored closely in these individuals who discontinue
TRUVADA. If appropriate anti-hepatitis B therapy may be
warranted. (5.1)
• TRUVADA used for HIV-1 PrEP must only be prescribed to
individuals confirmed to be HIV-negative immediately prior
to initiating and at least every 3 months during use. Drugresistant HIV-1 variants have been identified with the use of
TRUVADA for HIV-1 PrEP following undetected acute HIV-1
infection. Do not initiate TRUVADA for HIV-1 PrEP if signs
or symptoms of acute HIV infection are present unless
negative infection status is confirmed. (5.2)
----------------------------RECENT MAJOR CHANGES-------------------------Indications and Usage
HIV-1 Pre-Exposure Prophylaxis (PrEP) (1.2)
06/2020
Dosage and Administration
HIV-1 Screening for Individuals Receiving TRUVADA
for HIV-1 PrEP (2.2)
06/2020
Warnings and Precautions
Comprehensive Management to Reduce the Risk of
Sexually Transmitted Infections, Including
HIV-1, and Development of HIV-1 Resistance When
TRUVADA Is Used for HIV-1 PrEP (5.2)
06/2020
Immune Reconstitution Syndrome (5.4)
06/2020

o Creatinine clearance (CrCl) 30−49 mL/min: 1 tablet every 48
hours. (2.6)
o CrCl below 30 mL/min or hemodialysis: TRUVADA is not
recommended. (2.6)
HIV-1 Pre-Exposure Prophylaxis (PrEP)
• Recommended dosage in HIV-1 uninfected adults and adolescents
weighing at least 35 kg: One TRUVADA tablet (containing 200 mg
of FTC and 300 mg of TDF) once daily taken orally with or without
food. (2.5)
• Recommended dosage in renally impaired HIV-uninfected
individuals: TRUVADA is not recommended in HIV-uninfected
individuals if CrCl is below 60 mL/min. (2.6)
-----------------------DOSAGE FORMS AND STRENGTHS-------------------Tablets: 200 mg/300 mg, 167 mg/250 mg, 133 mg/200 mg, and 100
mg/150 mg of emtricitabine and tenofovir disoproxil fumarate,
respectively. (3)
--------------------------------CONTRAINDICATIONS-----------------------------TRUVADA for HIV-1 PrEP is contraindicated in individuals with
unknown or positive HIV-1 status. (4)
-------------------------WARNINGS AND PRECAUTIONS---------------------• Comprehensive management to reduce the risk of acquiring HIV-1
when TRUVADA is used for HIV-1 PrEP: Use as part of a
comprehensive prevention strategy including other prevention
measures; strictly adhere to dosing schedule. (5.2)
• Management to reduce the risk of acquiring HIV-1 drug resistance
when TRUVADA is used for HIV-1 PrEP: refer to full prescribing
information for additional detail. (5.2)
• New onset or worsening renal impairment: Can include acute renal
failure and Fanconi syndrome. Avoid administering TRUVADA with
concurrent or recent use of nephrotoxic drugs. (5.3)
• Immune reconstitution syndrome during treatment of HIV-1 infection:
May necessitate further evaluation and treatment. (5.4)
• Decreases in bone mineral density (BMD): Consider assessment of
BMD in individuals with a history of pathologic fracture or other risk
factors for osteoporosis or bone loss. (5.5)
• Lactic acidosis/severe hepatomegaly with steatosis: Discontinue
TRUVADA in individuals who develop symptoms or laboratory
findings suggestive of lactic acidosis or pronounced hepatotoxicity.
(5.6)

-------------------------------INDICATIONS AND USAGE------------------------HIV-1 Treatment (1.1)
TRUVADA is a two-drug combination of emtricitabine (FTC) and
tenofovir disoproxil fumarate (TDF), both HIV-1 nucleoside analog
reverse transcriptase inhibitors, and is indicated:
• in combination with other antiretroviral agents for the treatment of
HIV-1 infection in adults and pediatric patients weighing at least 17
kg.
HIV-1 PrEP (1.2):
• TRUVADA is indicated in at-risk adults and adolescents weighing at
least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of
sexually acquired HIV-1 infection. Individuals must have a negative
HIV-1 test immediately prior to initiating TRUVADA for HIV-1 PrEP.

--------------------------------ADVERSE REACTIONS----------------------------• In HIV-1 infected patients, the most common adverse reactions
(incidence greater than or equal to 10%) are diarrhea, nausea,
fatigue, headache, dizziness, depression, insomnia, abnormal
dreams, and rash. (6.1)
• In HIV-1 uninfected adults in PrEP trials, adverse reactions that
were reported by more than 2% of TRUVADA participants and more
frequently than by placebo participants were headache, abdominal
pain, and weight decreased. (6.1)

------------------------DOSAGE AND ADMINISTRATION---------------------• Testing: Prior to or when initiating TRUVADA test for hepatitis B
virus infection. Prior to initiation and during use of TRUVADA, on a
clinically appropriate schedule, assess serum creatinine, estimated
creatinine clearance, urine glucose, and urine protein in all
individuals. In individuals with chronic kidney disease, also assess
serum phosphorus. (2.1)
• HIV-1 Screening: Screen all individuals for HIV-1 infection
immediately prior to initiating TRUVADA for HIV-1 PrEP and at least
once every 3 months while taking TRUVADA, and upon diagnosis of
any other sexually transmitted infections (STIs). (2.2)
Treatment of HIV-1 Infection
• Recommended dosage in adults and pediatric patients weighing at
least 35 kg: One TRUVADA tablet (containing 200 mg of FTC and
300 mg of TDF) once daily taken orally with or without food. (2.3)
• Recommended dosage in pediatric patients weighing at least 17 kg:
One TRUVADA low-strength tablet (100 mg/150 mg, 133 mg/200
mg, or 167 mg/250 mg based on body weight) once daily taken
orally with or without food. (2.4)
• Recommended dosage in renally impaired HIV-1 infected adult
patients:

---------------------------------DRUG INTERACTIONS----------------------------• Tenofovir disoproxil fumarate increases didanosine concentrations.
Dose reduction and close monitoring for didanosine toxicity are
warranted. (7.2)
• Coadministration decreases atazanavir concentrations. When
coadministered with TRUVADA, use atazanavir given with ritonavir.
(7.2)
• Coadministration of TRUVADA with certain HIV-1 protease inhibitors
or certain drugs to treat HCV increases tenofovir concentrations.
Monitor for evidence of tenofovir toxicity. (7.2)
• Consult Full Prescribing Information prior to and during treatment for
important drug interactions. (7.2)

To report SUSPECTED ADVERSE REACTIONS, contact Gilead
Sciences, Inc. at 1-800-445-3235 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch

---------------------------USE IN SPECIFIC POPULATIONS-------------------Lactation: Mothers infected with HIV-1 or suspected of having
acquired HIV-1 infection should be instructed not to breastfeed due to
the potential for HIV transmission. (8.2)
See 17 for PATIENT COUNSELING INFORMATION and Medication
Guide.
Revised: 06/2020
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FULL PRESCRIBING INFORMATION
WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B and
RISK OF DRUG RESISTANCE WITH USE OF TRUVADA FOR HIV-1 PREEXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED EARLY HIV-1 INFECTION
Severe acute exacerbations of hepatitis B (HBV) have been reported in HBVinfected individuals who have discontinued TRUVADA. Hepatic function should
be monitored closely with both clinical and laboratory follow-up for at least
several months in individuals who are infected with HBV and discontinue
TRUVADA. If appropriate, anti-hepatitis B therapy may be warranted [see
Warnings and Precautions (5.1)].
TRUVADA used for HIV-1 PrEP must only be prescribed to individuals confirmed
to be HIV-negative immediately prior to initiating and at least every 3 months
during use. Drug-resistant HIV-1 variants have been identified with use of
TRUVADA for HIV-1 PrEP following undetected acute HIV-1 infection. Do not
initiate TRUVADA for HIV-1 PrEP if signs or symptoms of acute HIV-1 infection
are present unless negative infection status is confirmed [see Warnings and
Precautions (5.2)].
1

INDICATIONS AND USAGE

1.1

Treatment of HIV-1 Infection

TRUVADA is indicated in combination with other antiretroviral agents for the treatment of HIV-1
infection in adults and pediatric patients weighing at least 17 kg [see Clinical Studies (14)].
1.2

HIV-1 Pre-Exposure Prophylaxis (PrEP)

TRUVADA is indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure
prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Individuals must have a
negative HIV-1 test immediately prior to initiating TRUVADA for HIV-1 PrEP [see Dosage and
Administration (2.2), Warnings and Precautions (5.2)].
2

DOSAGE AND ADMINISTRATION

2.1

Testing Prior to Initiation of TRUVADA for Treatment of HIV-1 Infection or for HIV-1 PrEP

Prior to or when initiating TRUVADA, test individuals for hepatitis B virus infection [see Warnings and
Precautions (5.1)].
Prior to initiation, and during use of TRUVADA, on a clinically appropriate schedule, assess serum
creatinine, estimated creatinine clearance, urine glucose, and urine protein in all individuals. In
individuals with chronic kidney disease, also assess serum phosphorus [see Warnings and
Precautions (5.3)].
2.2

HIV-1 Screening for Individuals Receiving TRUVADA for HIV-1 PrEP

Screen all individuals for HIV-1 infection immediately prior to initiating TRUVADA for HIV-1 PrEP and
at least once every 3 months while taking TRUVADA, and upon diagnosis of any other sexually
transmitted infections (STIs) [see Indications and Usage (1.2), Contraindications (4), and Warnings
and Precautions (5.2)].
If recent (<1 month) exposures to HIV-1 are suspected or clinical symptoms consistent with acute
HIV-1 infection are present, use a test approved or cleared by the FDA as an aid in the diagnosis of
3

acute or primary HIV-1 infection [see Warnings and Precautions (5.2), Use in Specific Populations
(8.4), and Clinical Studies (14.3 and 14.4)].
2.3

Recommended Dosage for Treatment of HIV-1 Infection in Adults and Pediatric Patients
Weighing at Least 35 kg

TRUVADA is a two-drug fixed dose combination product containing emtricitabine (FTC) and tenofovir
disoproxil fumarate (TDF). The recommended dosage of TRUVADA in adults and in pediatric patients
weighing at least 35 kg is one tablet (containing 200 mg of FTC and 300 mg of TDF) once daily taken
orally with or without food [see Clinical Pharmacology (12.3)].
2.4

Recommended Dosage for Treatment of HIV-1 Infection in Pediatric Patients Weighing
at Least 17 kg and Able to Swallow a Tablet

The recommended oral dosage of TRUVADA for pediatric patients weighing at least 17 kg and who
can swallow a tablet is presented in Table 1. Tablets should be taken once daily with or without food.
Weight should be monitored periodically and the TRUVADA dose adjusted accordingly.
Table 1

2.5

Dosing for Treatment of HIV-1 Infection in Pediatric Patients Weighing 17 kg to less than
35 kg
Body Weight (kg)

Dosing of TRUVADA
(FTC/TDF)

17 to less than 22

one 100 mg /150 mg tablet once daily

22 to less than 28

one 133 mg /200 mg tablet once daily

28 to less than 35

one 167 mg /250 mg tablet once daily

Recommended Dosage for HIV-1 PrEP in Adults and Adolescents Weighing at Least 35
kg

The dosage of TRUVADA for HIV-1 PrEP is one tablet (containing 200 mg of FTC and 300 mg of
TDF) once daily taken orally with or without food in HIV-1 uninfected adults and adolescents weighing
at least 35 kg [see Clinical Pharmacology (12.3)].
2.6

Dosage Adjustment in Individuals with Renal Impairment

Treatment of HIV-1 Infection
Table 2 provides dosage interval adjustment for patients with renal impairment. No dosage
adjustment is necessary for HIV-1 infected patients with mild renal impairment (creatinine clearance
50–80 mL/min). The safety and effectiveness of the dosing interval adjustment recommendations in
patients with moderate renal impairment (creatinine clearance 30–49 mL/min) have not been clinically
evaluated; therefore, clinical response to treatment and renal function should be closely monitored in
these patients [see Warnings and Precautions (5.3)].
No data are available to make dosage recommendations in pediatric patients with renal impairment.

4

Table 2

Dosage Interval Adjustment for HIV-1 Infected Adult Patients with Altered Creatinine
Clearance
Creatinine Clearance (mL/min)a

Recommended Dosing
Interval
a.

50

30–49

<30
(Including Patients
Requiring Hemodialysis)

Every 24 hours

Every 48 hours

TRUVADA is not
recommended.

Calculated using ideal (lean) body weight

HIV-1 PrEP
TRUVADA for HIV-1 PrEP is not recommended in HIV-1 uninfected individuals with estimated
creatinine clearance below 60 mL/min [see Warnings and Precautions (5.3)].
If a decrease in estimated creatinine clearance is observed in uninfected individuals while using
TRUVADA for HIV-1 PrEP, evaluate potential causes and re-assess potential risks and benefits of
continued use [see Warnings and Precautions (5.3)].
3

DOSAGE FORMS AND STRENGTHS

TRUVADA tablets are available in four dose strengths.
•

100 mg/150 mg Tablets: 100 mg of emtricitabine (FTC) and 150 mg of tenofovir disoproxil
fumarate (TDF) (equivalent to 123 mg of tenofovir disoproxil): blue, oval shaped, film coated,
debossed with “GSI” on one side and with “703” on the other side.

•

133 mg/200 mg Tablets: 133 mg of FTC and 200 mg of TDF (equivalent to 163 mg of tenofovir
disoproxil): blue, rectangular shaped, film coated, debossed with “GSI” on one side and with “704”
on the other side.

•

167 mg/250 mg Tablets: 167 mg of FTC and 250 mg of TDF (equivalent to 204 mg of tenofovir
disoproxil): blue, modified capsule shaped, film coated, debossed with “GSI” on one side and with
“705” on the other side.

•

200 mg/300 mg Tablets: 200 mg of FTC and 300 mg of TDF (equivalent to 245 mg of tenofovir
disoproxil): blue, capsule shaped, film coated, debossed with “GILEAD” on one side and with
“701” on the other side.
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CONTRAINDICATIONS

TRUVADA for HIV-1 PrEP is contraindicated in individuals with unknown or positive HIV-1 status [see
Warnings and Precautions (5.2)].
5

WARNINGS AND PRECAUTIONS

5.1

Severe Acute Exacerbation of Hepatitis B in Individuals with HBV Infection

All individuals should be tested for the presence of chronic hepatitis B virus (HBV) before or when
initiating TRUVADA [see Dosage and Administration (2.1)].
Severe acute exacerbations of hepatitis B (e.g., liver decompensation and liver failure) have been
reported in HBV-infected individuals who have discontinued TRUVADA. Individuals infected with HBV
who discontinue TRUVADA should be closely monitored with both clinical and laboratory follow-up for
at least several months after stopping treatment. If appropriate, anti-hepatitis B therapy may be
warranted, especially in individuals with advanced liver disease or cirrhosis, since posttreatment
5

exacerbation of hepatitis may lead to hepatic decompensation and liver failure. HBV-uninfected
individuals should be offered vaccination.
5.2

Comprehensive Management to Reduce the Risk of Sexually Transmitted Infections,
Including HIV-1, and Development of HIV-1 Resistance When TRUVADA Is Used for HIV1 PrEP

Use TRUVADA for HIV-1 PrEP to reduce the risk of HIV-1 infection as part of a comprehensive
prevention strategy that includes other prevention measures, including adherence to daily
administration and safer sex practices, including condoms, to reduce the risk of sexually transmitted
infections (STIs). The time from initiation of TRUVADA for HIV-1 PrEP to maximal protection against
HIV-1 infection is unknown.
Risk for HIV-1 acquisition includes behavioral, biological, or epidemiologic factors including but not
limited to condomless sex, past or current STIs, self-identified HIV risk, having sexual partners of
unknown HIV-1 viremic status, or sexual activity in a high prevalence area or network.
Counsel individuals on the use of other prevention measures (e.g., consistent and correct condom
use, knowledge of partner(s)’ HIV-1 status, including viral suppression status, regular testing for STIs
that can facilitate HIV-1 transmission). Inform uninfected individuals about and support their efforts in
reducing sexual risk behavior.
Use TRUVADA to reduce the risk of acquiring HIV-1 only in individuals confirmed to be HIV-negative.
HIV-1 resistance substitutions may emerge in individuals with undetected HIV-1 infection who are
taking only TRUVADA, because TRUVADA alone does not constitute a complete regimen for HIV-1
treatment [see Microbiology (12.4)]; therefore, care should be taken to minimize the risk of initiating or
continuing TRUVADA before confirming the individual is HIV-1 negative.
•

Some HIV-1 tests only detect anti-HIV antibodies and may not identify HIV-1 during the acute
stage of infection. Prior to initiating TRUVADA for HIV-1 PrEP, ask seronegative individuals about
recent (in past month) potential exposure events (e.g., condomless sex or condom breaking
during sex with a partner of unknown HIV-1 status or unknown viremic status, or a recent STI),
and evaluate for current or recent signs or symptoms consistent with acute HIV-1 infection (e.g.,
fever, fatigue, myalgia, skin rash).

•

If recent (<1 month) exposures to HIV-1 are suspected or clinical symptoms consistent with acute
HIV-1 infection are present, use a test approved or cleared by the FDA as an aid in the diagnosis
of acute or primary HIV-1 infection.

While using TRUVADA for HIV-1 PrEP, HIV-1 testing should be repeated at least every 3 months,
and upon diagnosis of any other STIs.
•

If an HIV-1 test indicates possible HIV-1 infection, or if symptoms consistent with acute HIV-1
infection develop following a potential exposure event, convert the HIV-1 PrEP regimen to an HIV
treatment regimen until negative infection status is confirmed using a test approved or cleared by
the FDA as an aid in the diagnosis of acute or primary HIV-1 infection.

Counsel HIV-1 uninfected individuals to strictly adhere to the once daily TRUVADA dosing schedule.
The effectiveness of TRUVADA in reducing the risk of acquiring HIV-1 is strongly correlated with
adherence, as demonstrated by measurable drug levels in clinical trials of TRUVADA for HIV-1 PrEP.
Some individuals, such as adolescents, may benefit from more frequent visits and counseling to
support adherence [see Use in Specific Populations (8.4), Microbiology (12.4), and Clinical Studies
(14.3 and 14.4)].
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5.3

New Onset or Worsening Renal Impairment

Emtricitabine and tenofovir are principally eliminated by the kidney. Renal impairment, including
cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe
hypophosphatemia), has been reported with the use of TDF, a component of TRUVADA [see
Adverse Reactions (6.2)].
Prior to initiation and during use of TRUVADA, on a clinically appropriate schedule, assess serum
creatinine, estimated creatinine clearance, urine glucose, and urine protein in all individuals. In
individuals with chronic kidney disease, also assess serum phosphorus.
TRUVADA should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or
multiple non-steroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.1)]. Cases of acute
renal failure after initiation of high-dose or multiple NSAIDs have been reported in HIV-infected
patients with risk factors for renal dysfunction who appeared stable on TDF. Some patients required
hospitalization and renal replacement therapy. Alternatives to NSAIDs should be considered, if
needed, in patients at risk for renal dysfunction.
Persistent or worsening bone pain, pain in extremities, fractures, and/or muscular pain or weakness
may be manifestations of proximal renal tubulopathy and should prompt an evaluation of renal
function in individuals at risk of renal dysfunction.
Treatment of HIV-1 Infection
Dosing interval adjustment of TRUVADA and close monitoring of renal function are recommended in
all patients with estimated creatinine clearance 30–49 mL/min [see Dosage and Administration (2.6)].
No safety or efficacy data are available in patients with renal impairment who received TRUVADA
using these dosing guidelines, so the potential benefit of TRUVADA therapy should be assessed
against the potential risk of renal toxicity. TRUVADA is not recommended in patients with estimated
creatinine clearance below 30 mL/min or patients requiring hemodialysis.
HIV-1 PrEP
TRUVADA for HIV-1 PrEP is not recommended in uninfected individuals with estimated creatinine
clearance less than 60 mL/min. If a decrease in estimated creatinine clearance is observed while
using TRUVADA for HIV-1 PrEP, evaluate potential causes and re-assess potential risks and benefits
of continued use [see Dosage and Administration (2.6)].
5.4

Immune Reconstitution Syndrome

Immune reconstitution syndrome has been reported in HIV-1 infected patients treated with
combination antiretroviral therapy, including TRUVADA. During the initial phase of combination
antiretroviral treatment, HIV-1 infected patients whose immune system responds may develop an
inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium
infection, cytomegalovirus, Pneumocystis jirovecii pneumonia [PCP], or tuberculosis), which may
necessitate further evaluation and treatment.
Autoimmune disorders (such as Graves’ disease, polymyositis, Guillain-Barré syndrome, and
autoimmune hepatitis) have also been reported to occur in the setting of immune reconstitution;
however, the time to onset is more variable and can occur many months after initiation of treatment.
5.5

Bone Loss and Mineralization Defects

Bone Mineral Density
In clinical trials in HIV-1 infected adults and in a clinical trial of HIV-1 uninfected individuals, TDF (a
component of TRUVADA) was associated with slightly greater decreases in bone mineral density
(BMD) and increases in biochemical markers of bone metabolism, suggesting increased bone
7

turnover relative to comparators [see Adverse Reactions (6.1)]. Serum parathyroid hormone levels
and 1,25 Vitamin D levels were also higher in subjects receiving TDF.
Clinical trials evaluating TDF in pediatric and adolescent subjects were conducted. Under normal
circumstances, BMD increases rapidly in pediatric patients. In HIV-1 infected subjects aged 2 years to
less than 18 years, bone effects were similar to those observed in adult subjects and suggest
increased bone turnover. Total body BMD gain was less in the TDF-treated HIV-1 infected pediatric
subjects as compared to the control groups. Similar trends were observed in adolescent subjects
aged 12 years to less than 18 years treated for chronic hepatitis B. In all pediatric trials, skeletal
growth (height) appeared to be unaffected.
The effects of TDF-associated changes in BMD and biochemical markers on long-term bone health
and future fracture risk are unknown. Assessment of BMD should be considered for adult and
pediatric patients who have a history of pathologic bone fracture or other risk factors for osteoporosis
or bone loss. Although the effect of supplementation with calcium and vitamin D was not studied,
such supplementation may be beneficial. If bone abnormalities are suspected, appropriate
consultation should be obtained.
Mineralization Defects
Cases of osteomalacia associated with proximal renal tubulopathy, manifested as bone pain or pain
in extremities and which may contribute to fractures, have been reported in association with TDF use
[see Adverse Reactions (6.1)]. Arthralgia and muscle pain or weakness have also been reported in
cases of proximal renal tubulopathy. Hypophosphatemia and osteomalacia secondary to proximal
renal tubulopathy should be considered in patients at risk of renal dysfunction who present with
persistent or worsening bone or muscle symptoms while receiving TDF-containing products [see
Warnings and Precautions (5.3)].
5.6

Lactic Acidosis/Severe Hepatomegaly with Steatosis

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported
with the use of nucleoside analogs, including FTC and TDF, components of TRUVADA, alone or in
combination with other antiretrovirals. Treatment with TRUVADA should be suspended in any
individual who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced
hepatotoxicity (which may include hepatomegaly and steatosis even in the absence of marked
transaminase elevations).
5.7

Risk of Adverse Reactions Due to Drug Interactions

The concomitant use of TRUVADA and other drugs may result in known or potentially significant drug
interactions, some of which may lead to possible clinically significant adverse reactions from greater
exposures of concomitant drugs [see Drug Interactions (7.2)].
See Table 7 for steps to prevent or manage these possible and known significant drug interactions,
including dosing recommendations. Consider the potential for drug interactions prior to and during
therapy with TRUVADA; review concomitant medications during therapy with TRUVADA; and monitor
for adverse reactions associated with the concomitant drugs.
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ADVERSE REACTIONS

The following adverse reactions are discussed in other sections of the labeling:
•

Severe Acute Exacerbations of Hepatitis B in Patients with HBV Infection [see Warnings and
Precautions (5.1)].

•

New Onset or Worsening Renal Impairment [see Warnings and Precautions (5.3)].

•

Immune Reconstitution Syndrome [see Warnings and Precautions (5.4)].
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•

Bone Loss and Mineralization Defects [see Warnings and Precautions (5.5)].

•

Lactic Acidosis/Severe Hepatomegaly with Steatosis [see Warnings and Precautions (5.6)].

6.1

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates
observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of
another drug and may not reflect the rates observed in practice.
Adverse Reactions from Clinical Trials Experience in HIV-1 Infected Subjects
Clinical Trials in Adult Subjects
In Study 934, 511 antiretroviral-naïve subjects received efavirenz (EFV) administered in combination
with either FTC+TDF (N=257) or zidovudine (AZT)/lamivudine (3TC) (N=254) for 144 weeks. The
most common adverse reactions (incidence greater than or equal to 10%, all grades) included
diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, and rash.
Table 3 provides the treatment-emergent adverse reactions (Grades 2–4) occurring in greater than or
equal to 5% of subjects treated in any treatment group.
Skin discoloration, manifested by hyperpigmentation, occurred in 3% of subjects taking FTC+TDF,
and was generally mild and asymptomatic. The mechanism and clinical significance are unknown.
Table 3

Selected Adverse Reactionsa (Grades 2–4) Reported in 5% in Any Treatment Group in
Study 934 (0–144 Weeks)

Fatigue
Depression
Nausea
Diarrhea
Dizziness
Upper respiratory tract infections
Sinusitis
Rash eventc
Headache
Insomnia
Nasopharyngitis
Vomiting
a.
b.
c.

FTC+TDF+EFVb

AZT/3TC+EFV

N=257

N=254

9%
9%
9%
9%
8%
8%
8%
7%
6%
5%
5%
2%

8%
7%
7%
5%
7%
5%
4%
9%
5%
7%
3%
5%

Frequencies of adverse reactions are based on all treatment-emergent adverse events, regardless of relationship to study drug.
From Weeks 96 to 144 of the trial, subjects received TRUVADA with efavirenz in place of FTC+TDF with efavirenz.
Rash event includes rash, exfoliative rash, rash generalized, rash macular, rash maculo-papular, rash pruritic, and rash vesicular.

Laboratory Abnormalities: Laboratory abnormalities observed in this trial were generally consistent
with those seen in other trials of TDF and/or FTC (Table 4).
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Table 4

a.

Significant Laboratory Abnormalities Reported in 1% of Subjects in Any Treatment
Group in Study 934 (0–144 Weeks)
FTC+TDF+EFVa

AZT/3TC+EFV

N=257

N=254

Any  Grade 3 Laboratory
Abnormality

30%

26%

Fasting Cholesterol (>240 mg/dL)

22%

24%

Creatine Kinase
(M: >990 U/L)
(F: >845 U/L)

9%

7%

Serum Amylase (>175 U/L)

8%

4%

Alkaline Phosphatase (>550 U/L)

1%

0%

AST
(M: >180 U/L)
(F: >170 U/L)

3%

3%

ALT
(M: >215 U/L)
(F: >170 U/L)

2%

3%

Hemoglobin (<8.0 mg/dL)

0%

4%

Hyperglycemia (>250 mg/dL)

2%

1%

Hematuria (>75 RBC/HPF)

3%

2%

Glycosuria (3+)

<1%

1%

Neutrophils (<750/mm3)

3%

5%

Fasting Triglycerides (>750 mg/dL)

4%

2%

From Weeks 96 to 144 of the trial, subjects received TRUVADA with efavirenz in place of FTC+TDF with efavirenz.

Clinical Trials in Pediatric Subjects
Emtricitabine: In addition to the adverse reactions reported in adults, anemia and hyperpigmentation
were observed in 7% and 32%, respectively, of pediatric subjects (3 months to less than 18 years of
age) who received treatment with FTC in the larger of two open-label, uncontrolled pediatric trials
(N=116).
Tenofovir Disoproxil Fumarate: In pediatric clinical trials (Studies 352 and 321) conducted in 184 HIV1 infected subjects 2 to less than 18 years of age, the adverse reactions observed in pediatric
subjects who received treatment with TDF were consistent with those observed in clinical trials of
TDF in adults.
In Study 352 (2 to less than 12 years of age), 89 pediatric subjects received TDF for a median
exposure of 104 weeks. Of these, 4 subjects discontinued from the trial due to adverse reactions
consistent with proximal renal tubulopathy. Three of these 4 subjects presented with
hypophosphatemia and had decreases in total body or spine BMD Z-score [see Warnings and
Precautions (5.5)]. Total body BMD gain at Week 48 was less in the TDF group compared to the
stavudine (d4T) or zidovudine (AZT) treatment groups. The mean rate of BMD gain in lumbar spine
was similar between treatment groups. One TDF-treated subject and none of the d4T- or AZT-treated
subjects experienced significant (greater than 4%) lumbar spine BMD loss at Week 48. Changes from
baseline in BMD Z-scores were −0.012 for lumbar spine and −0.338 for total body in the 64 subjects
who were treated with TDF for 96 weeks.
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In Study 321 (12 to less than 18 years of age), the mean rate of BMD gain at Week 48 was less in the
TDF compared to the placebo treatment group. Six TDF-treated subjects and one placebo-treated
subject had significant (greater than 4%) lumbar spine BMD loss at Week 48. Changes from baseline
BMD Z-scores were −0.341 for lumbar spine and −0.458 for total body in the 28 subjects who were
treated with TDF for 96 weeks.
In both trials, skeletal growth (height) appeared to be unaffected.
Adverse Reactions from Clinical Trial Experience in Uninfected Subjects Taking TRUVADA for HIV-1
PrEP
Clinical Trials in Adult Subjects
The safety profile of TRUVADA for HIV-1 PrEP was comparable to that observed in clinical trials of
HIV-infected subjects based on two randomized placebo-controlled clinical trials (iPrEx, Partners
PrEP) in which 2,830 HIV-1 uninfected adults received TRUVADA once daily for HIV-1 PrEP.
Subjects were followed for a median of 71 weeks and 87 weeks, respectively. Table 5 provides a list
of selected adverse events that occurred in 2% or more of subjects in any treatment group in the
iPrEx trial, with an incidence greater than placebo.
Table 5

Selected Adverse Events (All Grades) Reported in 2% in Any Treatment Group in the
iPrEx Trial and Greater than Placebo
FTC/TDF
(N=1251)

Placebo
(N=1248)

7%
4%
3%

6%
2%
2%

Headache
Abdominal pain
Weight decreased

In the Partners PrEP trial, the frequency of adverse events in the TRUVADA treatment group was
generally either less than or the same as in the placebo group.
Laboratory Abnormalities: Table 6 provides a list of Grade 2-4 laboratory abnormalities observed in
the iPrEx and Partners PrEP trials. Six subjects in the TDF-containing arms of the Partners PrEP trial
discontinued from the trial due to an increase in serum creatinine compared with no discontinuations
in the placebo group. One subject in the TRUVADA arm of the iPrEx trial discontinued from the trial
due to an increase in serum creatinine and another subject discontinued due to low serum
phosphorus. Grades 2−3 proteinuria (2-4+) and/or glycosuria (3+) occurred in less than 1% of
subjects treated with TRUVADA in the iPrEx trial and Partners PrEP trial.
Table 6

Laboratory Abnormalities (Highest Toxicity Grade Reported for Each Subject) in the
iPrEx Trial and Partners PrEP Trial
iPrEx Trial

Partners PrEP Trial

FTC/TDF
(N=1251)

Placebo
(N=1248)

FTC/TDF
(N=1579)

Placebo
(N=1584)

Creatinine (>1.4  ULN)

<1%

<1%

<1%

<1%

Phosphorus (<2.0 mg/dL)

10%

8%

9%

9%

AST (>2.6  ULN)

5%

5%

<1%

<1%

ALT (>2.6  ULN)

7%

7%

<1%

<1%

Hemoglobin (<9.4 mg/dL)

1%

2%

2%

2%

Neutrophils (<750/mm3)

<1%

<1%

5%

3%

Grade 2-4a

a.

Grading is per DAIDS criteria.
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Changes in Bone Mineral Density: In clinical trials of HIV-1 uninfected individuals, decreases in BMD
were observed. In the iPrEx trial, a substudy of 503 subjects found mean changes from baseline in
BMD ranging from –0.4% to –1.0% across total hip, spine, femoral neck, and trochanter in the
TRUVADA group compared with the placebo group, which returned toward baseline after
discontinuation of treatment. Thirteen percent of TRUVADA-treated subjects versus 6% of placebotreated subjects lost at least 5% of BMD at the spine during treatment. Bone fractures were reported
in 1.7% of the TRUVADA group compared with 1.4% in the placebo group. No correlation between
BMD and fractures was noted [see Clinical Studies (14.3)]. The Partners PrEP trial found similar
fracture rates between the treatment and placebo groups (0.8% and 0.6%, respectively); no BMD
evaluations were performed in this trial [see Clinical Studies (14.4)].
Clinical Trials in Adolescent Subjects
In a single-arm, open-label clinical trial (ATN113), in which 67 HIV-1 uninfected adolescent (15 to 18
years of age) men who have sex with men received TRUVADA once daily for HIV-1 PrEP, the safety
profile of TRUVADA was similar to that observed in adults. Median duration to exposure of TRUVADA
was 47 weeks [see Use in Specific Populations (8.4)].
In the ATN113 trial, median BMD increased from baseline to Week 48, +2.58% for lumbar spine and
+0.72% for total body. One subject had significant (greater than or equal to 4%) total body BMD loss
at Week 24. Median changes from baseline BMD Z-scores were 0.0 for lumbar spine and −0.2 for
total body at Week 48. Three subjects showed a worsening (change from > −2 to ≤ −2) from baseline
in their lumbar spine or total body BMD Z-scores at Week 24 or 48. Interpretation of these data,
however, may be limited by the low rate of adherence to TRUVADA by Week 48.
6.2

Postmarketing Experience

The following adverse reactions have been identified during postapproval use of TDF. No additional
adverse reactions have been identified during postapproval use of FTC. Because postmarketing
reactions are reported voluntarily from a population of uncertain size, it is not always possible to
reliably estimate their frequency or establish a causal relationship to drug exposure.
Immune System Disorders
allergic reaction, including angioedema
Metabolism and Nutrition Disorders
lactic acidosis, hypokalemia, hypophosphatemia
Respiratory, Thoracic, and Mediastinal Disorders
dyspnea
Gastrointestinal Disorders
pancreatitis, increased amylase, abdominal pain
Hepatobiliary Disorders
hepatic steatosis, hepatitis, increased liver enzymes (most commonly AST, ALT gamma GT)
Skin and Subcutaneous Tissue Disorders
rash
Musculoskeletal and Connective Tissue Disorders
rhabdomyolysis, osteomalacia (manifested as bone pain and which may contribute to fractures),
muscular weakness, myopathy
Renal and Urinary Disorders
acute renal failure, renal failure, acute tubular necrosis, Fanconi syndrome, proximal renal
tubulopathy, interstitial nephritis (including acute cases), nephrogenic diabetes insipidus, renal
insufficiency, increased creatinine, proteinuria, polyuria
12

General Disorders and Administration Site Conditions
asthenia
The following adverse reactions, listed under the body system headings above, may occur as a
consequence of proximal renal tubulopathy: rhabdomyolysis, osteomalacia, hypokalemia, muscular
weakness, myopathy, hypophosphatemia.
7

DRUG INTERACTIONS

7.1

Drugs Affecting Renal Function

FTC and tenofovir are primarily excreted by the kidneys by a combination of glomerular filtration and
active tubular secretion [see Clinical Pharmacology (12.3)]. No drug-drug interactions due to
competition for renal excretion have been observed; however, coadministration of TRUVADA with
drugs that are eliminated by active tubular secretion may increase concentrations of FTC, tenofovir,
and/or the coadministered drug. Some examples include, but are not limited to, acyclovir, adefovir
dipivoxil, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and
high-dose or multiple NSAIDs [see Warnings and Precautions (5.3)]. Drugs that decrease renal
function may increase concentrations of FTC and/or tenofovir.
7.2

Established and Significant Interactions

Table 7 provides a listing of established or clinically significant drug interactions. The drug
interactions described are based on studies conducted with either TRUVADA, the components of
TRUVADA (FTC and TDF) as individual agents and/or in combination, or are predicted drug
interactions that may occur with TRUVADA [see Clinical Pharmacology (12.3)].
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Table 7

Established and Significanta Drug Interactions: Alteration in Dose or Regimen May Be
Recommended Based on Drug Interaction Trials

Concomitant Drug
Class: Drug Name
NRTI:
didanosinec

Effect on
Concentration
↑ didanosine

HIV-1 Protease
Inhibitors:
atazanavirc

↓ atazanavir

lopinavir/ritonavirc
atazanavir/ritonavirc
darunavir/ritonavirc

↑ tenofovir

Hepatitis C Antiviral
Agents:
sofosbuvir/velpatasvirc
sofosbuvir/velpatasvir/
voxilaprevirc

↑ tenofovir

ledipasvir/sofosbuvirc

Clinical Comment
Patients receiving TRUVADA and didanosine should be
monitored closely for didanosine-associated adverse
reactions. Discontinue didanosine in patients who develop
didanosine-associated adverse reactions. Higher didanosine
concentrations could potentiate didanosine-associated
adverse reactions, including pancreatitis, and neuropathy.
Suppression of CD4+ cell counts has been observed in
patients receiving TDF with didanosine 400 mg daily.
In patients weighing greater than 60 kg, reduce the
didanosine dose to 250 mg when it is coadministered with
TRUVADA. Data are not available to recommend a dose
adjustment of didanosine for adult or pediatric patients
weighing less than 60 kg. When coadministered, TRUVADA
and Videx EC may be taken under fasted conditions or with
a light meal (less than 400 kcal, 20% fat).
When coadministered with TRUVADA, atazanavir 300 mg
should be given with ritonavir 100 mg.

Monitor patients receiving TRUVADA concomitantly with
lopinavir/ritonavir, ritonavir-boosted atazanavir, or ritonavirboosted darunavir for TDF-associated adverse reactions.
Discontinue TRUVADA in patients who develop TDFassociated adverse reactions.
Monitor patients receiving TRUVADA concomitantly with
EPCLUSA® (sofosbuvir/velpatasvir) or VOSEVI®
(sofosbuvir/velpatasvir/voxilaprevir) for adverse reactions
associated with TDF.
Monitor patients receiving TRUVADA concomitantly with
HARVONI® (ledipasvir/sofosbuvir) without an HIV-1 protease
inhibitor/ritonavir or an HIV-1 protease inhibitor/cobicistat
combination for adverse reactions associated with TDF. In
patients receiving TRUVADA concomitantly with HARVONI
and an HIV-1 protease inhibitor/ritonavir or an HIV-1
protease inhibitor/cobicistat combination, consider an
alternative HCV or antiretroviral therapy, as the safety of
increased tenofovir concentrations in this setting has not
been established. If coadministration is necessary, monitor
for adverse reactions associated with TDF.

a. This table is not all inclusive.
b. ↑=Increase, ↓=Decrease
c. Indicates that a drug-drug interaction trial was conducted.
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8

USE IN SPECIFIC POPULATIONS

8.1

Pregnancy

Pregnancy Exposure Registry
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to
TRUVADA during pregnancy. Healthcare providers are encouraged to register patients by calling the
Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263.
Risk Summary
Data on the use of TRUVADA during pregnancy from observational studies have shown no increased
risk of major birth defects. Available data from the APR show no significant difference in the overall
risk of major birth defects with first trimester exposure for emtricitabine (FTC) (2.3%) or tenofovir
disoproxil fumarate (TDF) (2.1%) compared with the background rate for major birth defects of 2.7%
in a U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP) (see
Data). The rate of miscarriage for individual drugs is not reported in the APR. In the U.S. general
population, the estimated background risk of miscarriage in clinically recognized pregnancies is 15–
20%.
In animal reproduction studies, no adverse developmental effects were observed when the
components of TRUVADA were administered separately at doses/exposures ≥60 (FTC), ≥14 (TDF)
and 2.7 (tenofovir) times those of the recommended daily dose of TRUVADA (see Data).
Clinical Considerations
Disease-associated maternal and/or embryo/fetal risk
HIV-1 PrEP: Published studies indicate an increased risk of HIV-1 infection during pregnancy and an
increased risk of mother to child transmission during acute HIV-1 infection. In women at risk of
acquiring HIV-1, consideration should be given to methods to prevent acquisition of HIV, including
continuing or initiating TRUVADA for HIV-1 PrEP, during pregnancy.
Data
Human Data
TRUVADA for HIV-1 PrEP: In an observational study based on prospective reports to the APR, 78
HIV-seronegative women exposed to TRUVADA during pregnancy delivered live-born infants with no
major malformations. All but one were first trimester exposures, and the median duration of exposure
was 10.5 weeks. There were no new safety findings in the women receiving TRUVADA for HIV-1
PrEP compared with HIV-1 infected women treated with other antiretroviral medications.
Emtricitabine: Based on prospective reports to the APR of exposures to FTC-containing regimens
during pregnancy resulting in live births (including over 3,300 exposed in the first trimester and over
1,300 exposed in the second/third trimester), the prevalence of major birth defects in live births was
2.6% (95% CI: 2.1% to 3.2%) and 2.3% (95% CI: 1.6% to 3.3%) following first and second/third
trimester exposure, respectively, to FTC-containing regimens.
Tenofovir Disoproxil Fumarate: Based on prospective reports to the APR of exposures to TDFcontaining regimens during pregnancy resulting in live births (including over 4,000 exposed in the first
trimester and over 1,700 exposed in the second/third trimester), the prevalence of major birth defects
in live births was 2.4% (95% CI: 2.0% to 2.9%) and 2.4% (95% CI: 1.7% to 3.2%) following first and
second/third trimester exposure, respectively, to TDF-containing regimens.
Methodologic limitations of the APR include the use of MACDP as the external comparator group.
The MACDP population is not disease-specific, evaluates women and infants from a limited
geographic area, and does not include outcomes for births that occurred at <20 weeks gestation.
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Additionally, published observational studies on emtricitabine and tenofovir exposure in pregnancy
have not shown an increased risk for major malformations.
Animal Data
Emtricitabine: FTC was administered orally to pregnant mice (at 0, 250, 500, or 1,000 mg/kg/day),
and rabbits (at 0, 100, 300, or 1,000 mg/kg/day) through organogenesis (on gestation days 6 through
15, and 7 through 19, respectively). No significant toxicological effects were observed in embryo-fetal
toxicity studies performed with FTC in mice at exposures (AUC) approximately 60 times higher and in
rabbits at approximately 120 times higher than human exposures at the recommended daily dose. In
a pre/postnatal development study in mice, FTC was administered orally at doses up to 1,000
mg/kg/day; no significant adverse effects directly related to drug were observed in the offspring
exposed daily from before birth (in utero) through sexual maturity at daily exposures (AUC) of
approximately 60 times higher than human exposures at the recommended daily dose.
Tenofovir Disoproxil Fumarate: TDF was administered orally to pregnant rats (at 0, 50, 150, or 450
mg/kg/day) and rabbits (at 0, 30, 100, or 300 mg/kg/day) through organogenesis (on gestation days 7
through 17, and 6 through 18, respectively). No significant toxicological effects were observed in
embryo-fetal toxicity studies performed with TDF in rats at doses up to 14 times the human dose
based on body surface area comparisons and in rabbits at doses up to 19 times the human dose
based on body surface area comparisons. In a pre/postnatal development study in rats, TDF was
administered orally through lactation at doses up to 600 mg/kg/day; no adverse effects were
observed in the offspring at tenofovir exposures of approximately 2.7 times higher than human
exposures at the recommended daily dose of TRUVADA.
8.2

Lactation

Risk Summary
Based on published data, FTC and tenofovir have been shown to be present in human breast milk
(see Data). It is not known if the components of TRUVADA affect milk production or have effects on
the breastfed child.
Treatment of HIV-1 Infection:
The Centers for Disease Control and Prevention recommend that HIV-1 infected mothers not
breastfeed their infants to avoid risking postnatal transmission of HIV-1.
Because of the potential for: (1) HIV transmission (in HIV-negative infants); (2) developing viral
resistance (in HIV-positive infants); and (3) adverse reactions in a breastfed infant similar to those
seen in adults, instruct mothers not to breastfeed if they are taking TRUVADA for the treatment of
HIV-1.
HIV-1 PrEP:
In HIV-uninfected women, the developmental and health benefits of breastfeeding and the mother’s
clinical need for TRUVADA for HIV-1 PrEP should be considered along with any potential adverse
effects on the breastfed child from TRUVADA and the risk of HIV-1 acquisition due to nonadherence
and subsequent mother to child transmission.
Women should not breastfeed if acute HIV-1 infection is suspected because of the risk of HIV-1
transmission to the infant.
Data
HIV-1 PrEP: In a study of 50 breastfeeding women who received TRUVADA for HIV-1 PrEP between
1 and 24 weeks postpartum (median 13 weeks), after 7 days of treatment, tenofovir was undetectable
but FTC was detectable in the plasma of most infants. In these infants, the average FTC plasma
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concentration was less than 1% of the FTC Cmax observed in HIV-infected infants (up to 3 months of
age) receiving the therapeutic dose of FTC (3 mg/kg/day). There were no serious adverse events.
Two infants (4%) had an adverse event of mild diarrhea which resolved.
8.4

Pediatric Use

Treatment of HIV-1 Infection
No pediatric clinical trial was conducted to evaluate the safety and efficacy of TRUVADA in patients
with HIV-1 infection. Data from previously conducted trials with the individual drug products, FTC and
TDF, were relied upon to support dosage recommendations for TRUVADA. For additional
information, consult the prescribing information for EMTRIVA and VIREAD.
TRUVADA should only be administered to HIV-1 infected pediatric patients with body weight greater
than or equal to 17 kg and who are able to swallow a tablet. Because it is a fixed-dose combination
tablet, TRUVADA cannot be adjusted for patients of lower weight [see Warnings and Precautions
(5.5), Adverse Reactions (6.1) and Clinical Pharmacology (12.3)]. TRUVADA is not approved for use
in pediatric patients weighing less than 17 kg.
HIV-1 PrEP
The safety and effectiveness of TRUVADA for HIV-1 PrEP in at-risk adolescents weighing at least 35
kg is supported by data from adequate and well-controlled studies of TRUVADA for HIV-1 PrEP in
adults with additional data from safety and pharmacokinetic studies in previously conducted trials with
the individual drug products, FTC and TDF, in HIV-1 infected adults and pediatric subjects [see
Dosage and Administration (2.5), Adverse Reactions (6.1), Clinical Pharmacology (12.3 and 12.4),
and Clinical Studies (14.3 and 14.4)].
Safety, adherence, and resistance were evaluated in a single-arm, open-label clinical trial (ATN113)
in which 67 HIV-1 uninfected at-risk adolescent men who have sex with men received TRUVADA
once daily for HIV-1 PrEP. The mean age of subjects was 17 years (range 15 to 18 years); 46% were
Hispanic, 52% Black, and 37% White. The safety profile of TRUVADA in ATN113 was similar to that
observed in the adult HIV-1 PrEP trials [see Adverse Reactions (6.1)].
In the ATN113 trial, HIV-1 seroconversion occurred in 3 subjects. Tenofovir diphosphate levels in
dried blood spot assays indicate that these subjects had poor adherence. No tenofovir- or FTCassociated HIV-1 resistance substitutions were detected in virus isolated from the 3 subjects who
seroconverted [see Microbiology (12.4)].
Adherence to study drug, as demonstrated by tenofovir diphosphate levels in dried blood spot
assays, declined markedly after Week 12 once subjects switched from monthly to quarterly visits,
suggesting that adolescents may benefit from more frequent visits and counseling [see Warnings and
Precautions (5.2)].
Safety and effectiveness of Truvada for HIV-1 PrEP in pediatric patients weighing less than 35 kg
have not been established.
8.5

Geriatric Use

Clinical trials of FTC, TDF, or TRUVADA did not include sufficient numbers of subjects aged 65 and
over to determine whether they respond differently from younger subjects.
8.6

Renal Impairment

Treatment of HIV-1 Infection
The dosing interval for TRUVADA should be modified in HIV-infected adult individuals with estimated
creatinine clearance of 30–49 mL/min. TRUVADA is not recommended in individuals with estimated
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creatinine clearance below 30 mL/min and in individuals with end-stage renal disease requiring
dialysis [see Dosage and Administration (2.6)].
HIV-1 PrEP
TRUVADA for HIV-1 PrEP is not recommended in HIV-1 uninfected individuals with estimated
creatinine clearance below 60 mL/min. If a decrease in estimated creatinine clearance is observed in
uninfected individuals while using TRUVADA for HIV-1 PrEP, evaluate potential causes and reassess potential risks and benefits of continued use [see Dosage and Administration (2.6)].
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OVERDOSAGE

If overdose occurs, the patient must be monitored for evidence of toxicity, and standard supportive
treatment applied as necessary.
Emtricitabine: Hemodialysis treatment removes approximately 30% of the FTC dose over a 3-hour
dialysis period starting within 1.5 hours of FTC dosing (blood flow rate of 400 mL/min and a dialysate
flow rate of 600 mL/min). It is not known whether FTC can be removed by peritoneal dialysis.
Tenofovir Disoproxil Fumarate: Tenofovir is efficiently removed by hemodialysis with an extraction
coefficient of approximately 54%. Following a single 300 mg dose of TDF, a four-hour hemodialysis
session removed approximately 10% of the administered tenofovir dose.
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DESCRIPTION

TRUVADA tablets are fixed-dose combination tablets containing emtricitabine (FTC) and tenofovir
disoproxil fumarate (TDF). FTC is a synthetic nucleoside analog of cytidine. TDF is converted in vivo
to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5′-monophosphate.
Both FTC and tenofovir exhibit inhibitory activity against HIV-1 reverse transcriptase.
Emtricitabine: The chemical name of FTC is 5-fluoro-1-(2R,5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5yl]cytosine. FTC is the (-) enantiomer of a thio analog of cytidine, which differs from other cytidine
analogs in that it has a fluorine in the 5-position.
It has a molecular formula of C8H10FN3O3S and a molecular weight of 247.24. It has the following
structural formula:

H2N
F

N

O
N

O

OH

S
FTC is a white to off-white crystalline powder with a solubility of approximately 112 mg/mL in water at
25 C. The partition coefficient (log p) for emtricitabine is −0.43 and the pKa is 2.65.
Tenofovir Disoproxil Fumarate: TDF is a fumaric acid salt of the bis-isopropoxycarbonyloxymethyl
ester derivative of tenofovir. The chemical name of tenofovir DF is 9-[(R)-2
[[bis[[(isopropoxycarbonyl)oxy]- methoxy]phosphinyl]methoxy]propyl]adenine fumarate (1:1). It has a
molecular formula of C19H30N5O10P • C4H4O4 and a molecular weight of 635.52. It has the following
structural formula:
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Tenofovir disoproxil fumarate is a white to off-white crystalline powder with a solubility of 13.4 mg/mL
in water at 25 C. The partition coefficient (log p) for tenofovir disoproxil is 1.25 and the pKa is 3.75.
All dosages are expressed in terms of TDF except where otherwise noted.
TRUVADA tablets are for oral administration, and are available in the following strengths:
•

Film-coated tablet containing 200 mg of FTC and 300 mg of TDF (which is equivalent to 245 mg of
tenofovir disoproxil) as active ingredients

•

Film-coated tablet containing 167 mg of FTC and 250 mg of TDF (which is equivalent to 204 mg of
tenofovir disoproxil) as active ingredients

•

Film-coated tablet containing 133 mg of FTC and 200 mg of TDF (which is equivalent to 163 mg of
tenofovir disoproxil) as active ingredients

•

Film-coated tablet containing 100 mg of FTC and 150 mg of TDF (which is equivalent to 123 mg of
tenofovir disoproxil) as active ingredients

All strengths of TRUVADA tablets also include the following inactive ingredients: croscarmellose
sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and pregelatinized
starch (gluten free). The 200 mg/300 mg strength tablets are coated with Opadry II Blue Y-30-10701,
which contains FD&C Blue #2 aluminum lake, hypromellose 2910, lactose monohydrate, titanium
dioxide, and triacetin. The 167 mg/250 mg, 133 mg/200 mg, and 100 mg/150 mg strength tablets are
coated with Opadry II Blue, which contains FD&C Blue #2 aluminum lake, hypromellose 2910, lactose
monohydrate, titanium dioxide, and triacetin.
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CLINICAL PHARMACOLOGY

12.1

Mechanism of Action

TRUVADA is a fixed-dose combination of antiviral drugs FTC and TDF [see Microbiology (12.4)].
12.3

Pharmacokinetics

TRUVADA: One TRUVADA tablet was comparable to one FTC capsule (200 mg) plus one TDF tablet
(300 mg) following single-dose administration to fasting healthy subjects (N=39).
Emtricitabine: The pharmacokinetic properties of FTC are summarized in Table 8. Following oral
administration of FTC, FTC is rapidly absorbed with peak plasma concentrations occurring at 1–2
hours postdose. Less than 4% of FTC binds to human plasma proteins in vitro, and the binding is
independent of concentration over the range of 0.02–200 μg/mL. Following administration of
radiolabelled FTC, approximately 86% is recovered in the urine and 13% is recovered as metabolites.
The metabolites of FTC include 3′-sulfoxide diastereomers and their glucuronic acid conjugate.
Emtricitabine is eliminated by a combination of glomerular filtration and active tubular secretion.
Following a single oral dose of FTC, the plasma FTC half-life is approximately 10 hours.
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Tenofovir Disoproxil Fumarate: The pharmacokinetic properties of TDF are summarized in Table 8.
Following oral administration of TDF, maximum tenofovir serum concentrations are achieved in 1.0 
0.4 hour. Less than 0.7% of tenofovir binds to human plasma proteins in vitro, and the binding is
independent of concentration over the range of 0.01–25 g/mL. Approximately 70–80% of the
intravenous dose of tenofovir is recovered as unchanged drug in the urine. Tenofovir is eliminated by
a combination of glomerular filtration and active tubular secretion. Following a single oral dose of
TDF, the terminal elimination half-life of tenofovir is approximately 17 hours.
Table 8

Single Dose Pharmacokinetic Parameters for FTC and Tenofovir in Adultsa
FTC

Tenofovir

92 (83.1–106.4)

25 (NC–45.0)

10 (7.4–18.0)

17 (12.0–25.7)

1.80.72d

0.300.09

10.03.12d

2.290.69

CL/Fc (mL/min)

30294

1043115

CLrenalc (mL/min)

21389

24333

b

Fasted Oral Bioavailability (%)
Plasma Terminal Elimination Half-Lifeb (hr)
Cmaxc

(μg/mL)

AUCc (μg·hr/mL)

a.
b.
c.
d.

NC=Not calculated
Median (range)
Mean ( SD)
Data presented as steady state values

Effects of Food on Oral Absorption
TRUVADA may be administered with or without food. Administration of TRUVADA following a high fat
meal (784 kcal; 49 grams of fat) or a light meal (373 kcal; 8 grams of fat) delayed the time of tenofovir
Cmax by approximately 0.75 hour. The mean increases in tenofovir AUC and Cmax were approximately
35% and 15%, respectively, when administered with a high fat or light meal, compared to
administration in the fasted state. In previous safety and efficacy trials, TDF (tenofovir) was taken
under fed conditions. FTC systemic exposures (AUC and Cmax) were unaffected when TRUVADA was
administered with either a high fat or a light meal.
Specific Populations
Race
Emtricitabine: No pharmacokinetic differences due to race have been identified following the
administration of FTC.
Tenofovir Disoproxil Fumarate: There were insufficient numbers from racial and ethnic groups other
than Caucasian to adequately determine potential pharmacokinetic differences among these
populations following the administration of TDF.
Gender
Emtricitabine and Tenofovir Disoproxil Fumarate: FTC and tenofovir pharmacokinetics are similar in
male and female subjects.
Pediatric Patients
Treatment of HIV-1 Infection: The pharmacokinetic data for tenofovir and FTC following
administration of TRUVADA in pediatric subjects weighing 17 kg and above are not available. The
dosage recommendations of TRUVADA in this population are based on the dosage
recommendations of FTC and TDF in this population. Refer to the EMTRIVA and VIREAD prescribing
information for pharmacokinetic information on the individual products in pediatric patients.
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HIV-1 PrEP: The pharmacokinetic data for tenofovir and FTC following administration of TRUVADA in
HIV-1 uninfected adolescents weighing 35 kg and above are not available. The dosage
recommendations of TRUVADA for HIV-1 PrEP in this population are based on safety and adherence
data from the ATN113 trial [see Use in Specific Populations (8.4)] and known pharmacokinetic
information in HIV-infected adolescents taking TDF and FTC for treatment.
Geriatric Patients
Pharmacokinetics of FTC and tenofovir have not been fully evaluated in the elderly (65 years of age
and older).
Patients with Renal Impairment
The pharmacokinetics of FTC and tenofovir are altered in subjects with renal impairment [see
Warnings and Precautions (5.3)]. In adult subjects with creatinine clearance below 50 mL/min, Cmax
and AUC0- of FTC and tenofovir were increased. No data are available to make dosage
recommendations in pediatric patients with renal impairment.
Patients with Hepatic Impairment
The pharmacokinetics of tenofovir following a 300 mg dose of TDF have been studied in non-HIV
infected subjects with moderate to severe hepatic impairment. There were no substantial alterations
in tenofovir pharmacokinetics in subjects with hepatic impairment compared with unimpaired subjects.
The pharmacokinetics of TRUVADA or FTC have not been studied in subjects with hepatic
impairment; however, FTC is not significantly metabolized by liver enzymes, so the impact of liver
impairment should be limited.
Assessment of Drug Interactions
The steady state pharmacokinetics of FTC and tenofovir were unaffected when FTC and TDF were
administered together versus each agent dosed alone.
In vitro studies and clinical pharmacokinetic drug-drug interaction trials have shown that the potential
for CYP mediated interactions involving FTC and tenofovir with other medicinal products is low.
TDF is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP)
transporters. When TDF is coadministered with an inhibitor of these transporters, an increase in
absorption may be observed.
No clinically significant drug interactions have been observed between FTC and famciclovir, indinavir,
stavudine, TDF, and zidovudine (Tables 9 and 10). Similarly, no clinically significant drug interactions
have been observed between TDF and efavirenz, methadone, nelfinavir, oral contraceptives,
ribavirin, or sofosbuvir in trials conducted in healthy volunteers (Tables 11 and 12).
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Table 9

Drug Interactions: Changes in Pharmacokinetic Parameters for FTC in the Presence of
the Coadministered Druga
Dose of
Coadministered
Drug (mg)

FTC Dose
(mg)

TDF

300 once daily
 7 days

200 once daily
 7 days

Zidovudine

300 twice daily
 7 days

Indinavir

Coadministered
Drug

N

% Change of FTC Pharmacokinetic
Parametersb (90% CI)
Cmax

AUC

Cmin

17





 20
( 12 to  29)

200 once daily
 7 days

27







800  1

200  1

12





NA

Famciclovir

500  1

200  1

12





NA

Stavudine

40  1

200  1

6





NA

a.
b.

All interaction trials conducted in healthy volunteers
 = Increase;  = No Effect; NA = Not Applicable

Table 10

Drug Interactions: Changes in Pharmacokinetic Parameters for Coadministered Drug in
the Presence of FTCa
Dose of
Coadministered
Drug (mg)

FTC Dose
(mg)

TDF

300 once daily
 7 days

200 once daily
 7 days

Zidovudine

300 twice daily
 7 days

Indinavir

Coadministered
Drug

N

% Change of Coadministered
Drug Pharmacokinetic
Parametersb (90% CI)
Cmax

AUC

Cmin

17







200 once daily
 7 days

27

 17
( 0 to  38)

 13
( 5 to  20)



800  1

200  1

12





NA

Famciclovir

500  1

200  1

12





NA

Stavudine

40  1

200  1

6





NA

a.
b.

All interaction trials conducted in healthy volunteers
 = Increase;  = No Effect; NA = Not Applicable
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Table 11

Drug Interactions: Changes in Pharmacokinetic Parameters for Tenofovira in the
Presence of the Coadministered Drug
Dose of
Coadministered
Drug (mg)

N

Atazanavirc

400 once daily
 14 days

Atazanavir/
Ritonavirc
Darunavir/
Ritonavird

Coadministered
Drug

Indinavir
Ledipasvir/
Sofosbuvire,f
Ledipasvir/
Sofosbuvire,g

% Change of Tenofovir Pharmacokinetic Parametersb
(90% CI)
Cmax

AUC

Cmin

33

 14
( 8 to  20)

 24
( 21 to  28)

 22
( 15 to  30)

300/100 once
daily

12

 34
( 20 to  51)

 37
( 30 to  45)

 29
( 21 to  36)

300/100 twice
daily

12

 24
( 8 to  42)

 22
( 10 to  35)

 37
( 19 to  57)

800 three times
daily  7 days

13

 14
( 3 to  33)





24

 47
( 37 to  58)

 35
( 29 to 42 )

 47
( 38 to  57)

23

 64
( 54 to  74)

 50
( 42 to  59)

 59
( 49 to  70)

90/400 once daily
 10 days

Ledipasvir/
Sofosbuvirh

90/400 once daily
 14 days

15

 79
( 56 to  104)

 98
( 77 to  123)

 163
( 132 to  197)

Ledipasvir/
Sofosbuviri

90/400 once daily
 10 days

14

 32
( 25 to  39 )

 40
( 31 to  50 )

 91
( 74 to  110)

Ledipasvir/
Sofosbuvirj

90/400 once daily
 10 days

29

 61
( 51 to  72)

 65
( 59 to  71)

 115
( 105 to  126)

Lopinavir/
Ritonavir

400/100 twice
daily  14 days

24



 32
( 25 to  38)

 51
( 37 to  66)

Saquinavir/
Ritonavir

1000/100 twice
daily  14 days

35





 23
( 16 to  30)

Sofosbuvirk

400 single dose

16

 25
( 8 to  45)





Sofosbuvir/
Velpatasvirl

400/100 once
daily

24

 44
( 33 to  55)

 40
( 34 to  46)

 84
( 76 to  92)

Sofosbuvir/
Velpatasvirm

400/100 once
daily

30

 46
( 39 to  54)

 40
( 34 to  45)

 70
( 61 to  79)

Sofosbuvir/
Velpatasvir/
Voxilaprevirn

400/100/100 +
Voxilapreviro 100
once daily

29

 48
( 36 to  61)

 39
( 32 to  46)

 47
( 38 to  56)

Tacrolimus

0.05 mg/kg twice
daily  7 days

21

 13
( 1 to  27)





500/100 twice
daily

22

 23
( 32 to  13)

2
( 9 to  5)

7
( 2 to  17)

750/200 twice
daily (23 doses)

20

 38
( 46 to  29)

2
( 6 to  10)

 14
( 1 to  27)

Tipranavir/
Ritonavirp
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a.
b.
c.
d.
e.

Subjects received VIREAD 300 mg once daily.
Increase = ; Decrease = ; No Effect = 
Reyataz Prescribing Information.
Prezista Prescribing Information.
Data generated from simultaneous dosing with HARVONI (ledipasvir/sofosbuvir). Staggered administration (12 hours apart)
provided similar results.
f. Comparison based on exposures when administered as atazanavir/ritonavir + FTC/TDF.
g. Comparison based on exposures when administered as darunavir/ritonavir + FTC/TDF.
h. Study conducted with ATRIPLA (efavirenz/FTC/TDF) coadministered with HARVONI.
i.
Study conducted with COMPLERA (FTC/rilpivirine/TDF) coadministered with HARVONI.
j.
Study conducted with TRUVADA (FTC/TDF) + dolutegravir coadministered with HARVONI.
k. Study conducted with ATRIPLA coadministered with SOVALDI® (sofosbuvir).
l.
Study conducted with COMPLERA coadministered with EPCLUSA; coadministration with EPCLUSA also results in comparable
increases in tenofovir exposures when TDF is administered as ATRIPLA, STRIBILD, TRUVADA + atazanavir/ritonavir, or
TRUVADA + darunavir/ritonavir.
m. Administered as raltegravir + FTC/TDF.
n. Comparison based on exposures when administered as darunavir + ritonavir + FTC/TDF.
o. Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposures expected in HCV-infected patients
p. Aptivus Prescribing Information.

No effect on the pharmacokinetic parameters of the following coadministered drugs was observed with
TRUVADA: abacavir, didanosine (buffered tablets), FTC, entecavir, and lamivudine.
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Table 12

Drug Interactions: Changes in Pharmacokinetic Parameters for Coadministered Drug in
the Presence of Tenofovir
Dose of
Coadministered
Drug (mg)

N

300 once

Atazanavirb

Coadministered
Drug

Cmax

AUC

Cmin

8

 12
( 1 to  26)



NA

400 once daily
 14 days

34

 21
( 27 to  14)

 25
( 30 to  19)

 40
( 48 to  32)

Atazanavirb

Atazanavir/Ritonavir
300/100 once daily
 42 days

10

 28
( 50 to  5)

 25c
( 42 to  3)

 23c
( 46 to  10)

Darunavird

Darunavir/Ritonavir
300/100 once daily

12

 16
( 6 to  42)

 21
( 5 to  54)

 24
( 10 to  69)

250 once,
simultaneously with
TDF and a light
mealf

33

 20g
( 32 to  7)

g

NA

200 once daily
 7 days

17





 20
( 12 to  29)

Indinavir

800 three times daily
 7 days

12

 11
( 30 to  12)





Entecavir

1 once daily  10
days

28



 13
( 11 to  15)



150 twice daily
 7 days

15

 24
( 34 to  12)





Lopinavir/Ritonavir
400/100 twice daily
 14 days

24










 22
( 6 to 41)

 29h
( 12 to  48)

 47h
( 23 to  76)





 23
( 3 to  46)

Abacavir

Didanosine

e

Emtricitabine

Lamivudine
Lopinavir
Ritonavir
Saquinavir

Ritonavir

Tacrolimus

Tipranaviri

a.
b.
c.
d.
e.

f.
g.

% Change of Coadministered Drug
Pharmacokinetic Parametersa
(90% CI)

Saquinavir/Ritonavir
1000/100 twice daily
 14 days

32

0.05 mg/kg twice
daily  7 days

21







Tipranavir/Ritonavir
500/100 twice daily

22

 17
( 26 to  6)

 18
( 25 to  9)

 21
( 30 to  10)

Tipranavir/Ritonavir
750/200 twice daily
(23 doses)

20

 11
( 16 to  4)

9
( 15 to  3)

 12
( 22 to 0)

Increase = ; Decrease = ; No Effect = ; NA = Not Applicable
Reyataz Prescribing Information.
In HIV-infected subjects, addition of TDF to atazanavir 300 mg plus ritonavir 100 mg resulted in AUC and Cmin values of atazanavir
that were 2.3- and 4-fold higher than the respective values observed for atazanavir 400 mg when given alone.
Prezista Prescribing Information.
Videx EC Prescribing Information. Subjects received didanosine enteric-coated capsules. When didanosine 250 mg enteric-coated
capsules were administered with TDF, systemic exposures of didanosine were similar to those seen with the 400 mg entericcoated capsules alone under fasted conditions.
373 kcal, 8.2 g fat
Compared with didanosine (enteric-coated) 400 mg administered alone under fasting conditions.
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h.
i.

Increases in AUC and Cmin are not expected to be clinically relevant; hence, no dose adjustments are required when TDF and
ritonavir-boosted saquinavir are coadministered.
Aptivus Prescribing Information.

12.4

Microbiology

Mechanism of Action
Emtricitabine: FTC, a synthetic nucleoside analog of cytidine, is phosphorylated by cellular enzymes
to form emtricitabine 5'-triphosphate (FTC-TP), which inhibits the activity of the HIV-1 reverse
transcriptase (RT) by competing with the natural substrate deoxycytidine 5'-triphosphate and by being
incorporated into nascent viral DNA which results in chain termination. FTC-TP is a weak inhibitor of
mammalian DNA polymerases , ,  and mitochondrial DNA polymerase .
Tenofovir Disoproxil Fumarate: TDF is an acyclic nucleoside phosphonate diester analog of
adenosine monophosphate. TDF requires initial diester hydrolysis for conversion to tenofovir and
subsequent phosphorylations by cellular enzymes to form tenofovir diphosphate (TFV-DP), which
inhibits the activity of HIV-1 RT by competing with the natural substrate deoxyadenosine 5′triphosphate and, after incorporation into DNA, by DNA chain termination. TFV-DP is a weak inhibitor
of mammalian DNA polymerases , , and mitochondrial DNA polymerase .
Antiviral Activity
Emtricitabine and Tenofovir Disoproxil Fumarate: No antagonism was observed in combination
studies evaluating the cell culture antiviral activity of FTC and tenofovir together.
Emtricitabine: The antiviral activity of FTC against laboratory and clinical isolates of HIV-1 was
assessed in lymphoblastoid cell lines, the MAGI-CCR5 cell line, and peripheral blood mononuclear
cells. The 50% effective concentration (EC50) values for FTC were in the range of 0.0013–0.64 M
(0.0003–0.158 g/mL). In drug combination studies of FTC with nucleoside RT inhibitors (abacavir,
lamivudine, stavudine, zidovudine), non-nucleoside RT inhibitors (delavirdine, efavirenz, nevirapine),
and protease inhibitors (amprenavir, nelfinavir, ritonavir, saquinavir), no antagonism was observed.
Emtricitabine displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, and G
(EC50 values ranged from 0.007–0.075 M) and showed strain-specific activity against HIV-2 (EC50
values ranged from 0.007–1.5 M).
Tenofovir Disoproxil Fumarate: The antiviral activity of tenofovir against laboratory and clinical
isolates of HIV-1 was assessed in lymphoblastoid cell lines, primary monocyte/macrophage cells, and
peripheral blood lymphocytes. The EC50 values for tenofovir were in the range of 0.04–8.5 M. In
drug combination studies of tenofovir with nucleoside RT inhibitors (abacavir, didanosine, lamivudine,
stavudine, zidovudine), non-nucleoside RT inhibitors (delavirdine, efavirenz, nevirapine), and
protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir, saquinavir), no antagonism was
observed. Tenofovir displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, G,
and O (EC50 values ranged from 0.5–2.2 M) and showed strain-specific activity against HIV-2 (EC50
values ranged from 1.6 M to 5.5 M).
Prophylactic Activity in a Nonhuman Primate Model of HIV-1 Transmission
Emtricitabine and Tenofovir Disoproxil Fumarate: The prophylactic activity of the combination of daily
oral FTC and TDF was evaluated in a controlled study of macaques inoculated once weekly for 14
weeks with SIV/HIV-1 chimeric virus (SHIV) applied to the rectal surface. Of the 18 control animals,
17 became infected after a median of 2 weeks. In contrast, 4 of the 6 animals treated daily with oral
FTC and TDF remained uninfected and the two infections that did occur were significantly delayed
until 9 and 12 weeks and exhibited reduced viremia. An M184I-expressing FTC-resistant variant
emerged in 1 of the 2 macaques after 3 weeks of continued drug exposure.

26

Resistance
Emtricitabine and Tenofovir Disoproxil Fumarate: HIV-1 isolates with reduced susceptibility to the
combination of FTC and tenofovir have been selected in cell culture. Genotypic analysis of these
isolates identified the M184V/I and/or K65R amino acid substitutions in the viral RT. In addition, a
K70E substitution in the HIV-1 RT has been selected by tenofovir and results in reduced susceptibility
to tenofovir.
In Study 934, a clinical trial of treatment-naïve subjects [see Clinical Studies (14.2)], resistance
analysis was performed on HIV-1 isolates from all confirmed virologic failure subjects with greater
than 400 copies/mL of HIV-1 RNA at Week 144 or early discontinuation. Development of efavirenz
resistance-associated substitutions occurred most frequently and was similar between the treatment
arms. The M184V amino acid substitution, associated with resistance to FTC and lamivudine, was
observed in 2/19 analyzed subject isolates in the FTC+TDF group and in 10/29 analyzed subject
isolates in the zidovudine/lamivudine group. Through 144 weeks of Study 934, no subjects have
developed a detectable K65R or K70E substitution in their HIV-1 as analyzed through standard
genotypic analysis.
Emtricitabine: FTC-resistant isolates of HIV-1 have been selected in cell culture and in vivo.
Genotypic analysis of these isolates showed that the reduced susceptibility to FTC was associated
with a substitution in the HIV-1 RT gene at codon 184 which resulted in an amino acid substitution of
methionine by valine or isoleucine (M184V/I).
Tenofovir Disoproxil Fumarate: HIV-1 isolates with reduced susceptibility to tenofovir have been
selected in cell culture. These viruses expressed a K65R substitution in RT and showed a 2- to 4-fold
reduction in susceptibility to tenofovir.
In treatment-naïve subjects, isolates from 8/47 (17%) analyzed subjects developed the K65R
substitution in the TDF arm through 144 weeks; 7 occurred in the first 48 weeks of treatment and 1 at
Week 96. In treatment-experienced subjects, 14/304 (5%) isolates from subjects failing TDF through
Week 96 showed greater than 1.4-fold (median 2.7) reduced susceptibility to tenofovir. Genotypic
analysis of the resistant isolates showed a K65R amino acid substitution in the HIV-1 RT.
iPrEx Trial: In the iPrEx trial, a clinical trial of HIV-1 seronegative adult subjects [see Clinical Studies
(14.3)], no amino acid substitutions associated with resistance to FTC or TDF were detected at the
time of seroconversion among 48 subjects in the TRUVADA group and 83 subjects in the placebo
group who became infected with HIV-1 during the trial. Ten subjects were observed to be HIV-1
infected at time of enrollment. The M184V/I substitutions associated with resistance to FTC were
observed in 3 of the 10 subjects (2 of 2 in the TRUVADA group and 1 of 8 in the placebo group). One
of the two subjects in the TRUVADA group harbored wild type virus at enrollment and developed the
M184V substitution 4 weeks after enrollment. The other subject had indeterminate resistance at
enrollment but was found to have the M184I substitution 4 weeks after enrollment.
Partners PrEP Trial: In the Partners PrEP trial, a clinical trial of HIV-1 seronegative adult subjects
[see Clinical Studies (14.4)], no variants expressing amino acid substitutions associated with
resistance to FTC or TDF were detected at the time of seroconversion among 12 subjects in the
TRUVADA group, 15 subjects in the TDF group, and 51 subjects in the placebo group. Fourteen
subjects were observed to be HIV-1 infected at the time of enrollment (3 in the TRUVADA group, 5 in
the TDF group, and 6 in the placebo group). One of the three subjects in the TRUVADA group who
was infected with wild type virus at enrollment selected an M184V expressing virus by Week 12. Two
of the five subjects in the TDF group had tenofovir-resistant viruses at the time of seroconversion;
one subject infected with wild type virus at enrollment developed a K65R substitution by Week 16,
while the second subject had virus expressing the combination of D67N and K70R substitutions upon
seroconversion at Week 60, although baseline virus was not genotyped and it is unclear if the
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resistance emerged or was transmitted. Following enrollment, 4 subjects (2 in the TDF group, 1 in the
TRUVADA group, and 1 in the placebo group) had virus expressing K103N or V106A substitutions,
which confer high-level resistance to NNRTIs but have not been associated with FTC or TDF and
may have been present in the infecting virus.
ATN113 Trial: In ATN113, a clinical trial of HIV-1 seronegative adolescent subjects [see Use in
Specific Populations (8.4)], no amino acid substitutions associated with resistance to FTC or TDF
were detected at the time of seroconversion from any of the 3 subjects who became infected with
HIV-1 during the trial. All 3 subjects who seroconverted were nonadherent to the recommended
TRUVADA dosage.
Cross Resistance
Emtricitabine and Tenofovir Disoproxil Fumarate: Cross-resistance among certain NRTIs has been
recognized. The M184V/I and/or K65R substitutions selected in cell culture by the combination of
FTC and tenofovir are also observed in some HIV-1 isolates from subjects failing treatment with
tenofovir in combination with either FTC or lamivudine, and either abacavir or didanosine. Therefore,
cross-resistance among these drugs may occur in patients whose virus harbors either or both of
these amino acid substitutions.
Emtricitabine: FTC-resistant isolates (M184V/I) were cross-resistant to lamivudine but retained
susceptibility in cell culture to the NRTIs didanosine, stavudine, tenofovir, and zidovudine, and to
NNRTIs (delavirdine, efavirenz, and nevirapine). HIV-1 isolates containing the K65R substitution,
selected in vivo by abacavir, didanosine, and tenofovir, demonstrated reduced susceptibility to
inhibition by FTC. Viruses harboring substitutions conferring reduced susceptibility to stavudine and
zidovudine (M41L, D67N, K70R, L210W, T215Y/F, K219Q/E), or didanosine (L74V) remained
sensitive to FTC. HIV-1 containing the K103N substitution associated with resistance to NNRTIs was
susceptible to FTC.
Tenofovir Disoproxil Fumarate: The K65R and K70E substitutions selected by tenofovir are also
selected in some HIV-1 infected patients treated with abacavir or didanosine. HIV-1 isolates with the
K65R and K70E substitutions also showed reduced susceptibility to FTC and lamivudine. Therefore,
cross-resistance among these NRTIs may occur in patients whose virus harbors the K65R or K70E
substitutions. HIV-1 isolates from subjects (N=20) whose HIV-1 expressed a mean of 3 zidovudineassociated RT amino acid substitutions (M41L, D67N, K70R, L210W, T215Y/F, or K219Q/E/N)
showed a 3.1-fold decrease in the susceptibility to tenofovir. Subjects whose virus expressed an L74V
substitution without zidovudine resistance-associated substitutions (N=8) had reduced response to
TDF. Limited data are available for patients whose virus expressed a Y115F substitution (N=3),
Q151M substitution (N=2), or T69 insertion (N=4), all of whom had a reduced response.
13

NONCLINICAL TOXICOLOGY

13.1

Carcinogenesis, Mutagenesis, Impairment of Fertility

Emtricitabine: In long-term oral carcinogenicity studies of FTC, no drug-related increases in tumor
incidence were found in mice at doses up to 750 mg/kg/day (26 times the human systemic exposure
at the therapeutic dose of 200 mg/day) or in rats at doses up to 600 mg/kg/day (31 times the human
systemic exposure at the therapeutic dose).
FTC was not genotoxic in the reverse mutation bacterial test (Ames test), or the mouse lymphoma or
mouse micronucleus assays.
FTC did not affect fertility in male rats at approximately 140-fold or in male and female mice at
approximately 60-fold higher exposures (AUC) than in humans given the recommended 200 mg daily
dose. Fertility was normal in the offspring of mice exposed daily from before birth (in utero) through
28

sexual maturity at daily exposures (AUC) of approximately 60-fold higher than human exposures at
the recommended 200 mg daily dose.
Tenofovir Disoproxil Fumarate: Long-term oral carcinogenicity studies of TDF in mice and rats were
carried out at exposures up to approximately 16 times (mice) and 5 times (rats) those observed in
humans at the therapeutic dose for HIV-1 infection. At the high dose in female mice, liver adenomas
were increased at exposures 16 times that in humans. In rats, the study was negative for
carcinogenic findings at exposures up to 5 times that observed in humans at the therapeutic dose.
TDF was mutagenic in the in vitro mouse lymphoma assay and negative in an in vitro bacterial
mutagenicity test (Ames test). In an in vivo mouse micronucleus assay, TDF was negative when
administered to male mice.
There were no effects on fertility, mating performance, or early embryonic development when TDF
was administered to male rats at a dose equivalent to 10 times the human dose based on body
surface area comparisons for 28 days prior to mating and to female rats for 15 days prior to mating
through day 7 of gestation. There was, however, an alteration of the estrous cycle in female rats.
13.2

Animal Toxicology and/or Pharmacology

Tenofovir and TDF administered in toxicology studies to rats, dogs, and monkeys at exposures
(based on AUCs) greater than or equal to 6-fold those observed in humans caused bone toxicity. In
monkeys the bone toxicity was diagnosed as osteomalacia. Osteomalacia observed in monkeys
appeared to be reversible upon dose reduction or discontinuation of tenofovir. In rats and dogs, the
bone toxicity manifested as reduced bone mineral density. The mechanism(s) underlying bone
toxicity is unknown.
Evidence of renal toxicity was noted in four animal species. Increases in serum creatinine, BUN,
glycosuria, proteinuria, phosphaturia, and/or calciuria and decreases in serum phosphate were
observed to varying degrees in these animals. These toxicities were noted at exposures (based on
AUCs) 2–20 times higher than those observed in humans. The relationship of the renal abnormalities,
particularly the phosphaturia, to the bone toxicity is not known.
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CLINICAL STUDIES

14.1

Overview of Clinical Trials

The efficacy and safety of TRUVADA have been evaluated in the studies summarized in Table 13.
Table 13

a.
b.
c.

Trials Conducted with TRUVADA for HIV-1 Treatment and HIV-1 PrEP

Trial

Population

Study Arms (N)a

Timepoint

Study 934b
(NCT00112047)

HIV-infected, treatment-naïve
adults

FTC+TDF + efavirenz (257)
zidovudine/lamivudine +
efavirenz (254)

48 Weeks

iPrExc
(NCT00458393)

HIV-seronegative men or
transgender women who have
sex with men

TRUVADA (1,251)
Placebo (1,248)

4,237 person-years

Partners PrEPc
(NCT00557245)

HIV serodiscordant
heterosexual couples

TRUVADA (1,583)
Placebo (1,586)

7,827 person-years

Randomized and dosed.
Randomized, open label, active-controlled trial.
Randomized, double-blind, placebo-controlled trial.

14.2

Clinical Trial Results for Treatment of HIV-1: Study 934

Data through 144 weeks are reported for Study 934, a randomized, open-label, active-controlled
multicenter trial comparing FTC+TDF administered in combination with efavirenz (EFV) versus
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zidovudine (AZT)/lamivudine (3TC) fixed-dose combination administered in combination with EFV in
511 antiretroviral-naïve adult subjects. From Weeks 96 to 144 of the trial, subjects received
TRUVADA with EFV in place of FTC+TDF with EFV. Subjects had a mean age of 38 years (range
18–80); 86% were male, 59% were Caucasian, and 23% were Black. The mean baseline CD4+ cell
count was 245 cells/mm3 (range 2–1,191) and median baseline plasma HIV-1 RNA was 5.01 log10
copies/mL (range 3.56–6.54). Subjects were stratified by baseline CD4+ cell count (< or 200
cells/mm3); 41% had CD4+ cell counts <200 cells/mm3 and 51% of subjects had baseline viral loads
>100,000 copies/mL. Treatment outcomes through 48 and 144 weeks for those subjects who did not
have EFV resistance at baseline are presented in Table 14.
Table 14

Virologic Outcomes of Randomized Treatment at Weeks 48 and 144 (Study 934)
At Week 48

Outcomes

FTC+TDF
+EFV
(N=244)

AZT/3TC
+EFV
(N=243)

FTC+TDF
+EFV
(N=227)a

AZT/3TC
+EFV
(N=229)a

Responderb

84%

73%

71%

58%

Virologic failurec

2%

4%

3%

6%

Rebound

1%

3%

2%

5%

Never suppressed

0%

0%

0%

0%

Change in antiretroviral regimen

1%

1%

1%

1%

<1%

1%

1%

1%

4%

9%

5%

12%

10%

14%

20%

22%

Death
Discontinued due to adverse event
Discontinued for other reasons
a.
b.
c.
d.

At Week 144

d

Subjects who were responders at Week 48 or Week 96 (HIV-1 RNA <400 copies/mL) but did not consent to continue trial after
Week 48 or Week 96 were excluded from analysis.
Subjects achieved and maintained confirmed HIV-1 RNA <400 copies/mL through Weeks 48 and 144.
Includes confirmed viral rebound and failure to achieve confirmed <400 copies/mL through Weeks 48 and 144.
Includes lost to follow-up, subject withdrawal, noncompliance, protocol violation, and other reasons.

Through Week 48, 84% and 73% of subjects in the FTC+TDF group and the AZT/3TC group,
respectively, achieved and maintained HIV-1 RNA <400 copies/mL (71% and 58% through Week
144). The difference in the proportion of subjects who achieved and maintained HIV-1 RNA
<400 copies/mL through 48 weeks is largely due to the higher number of discontinuations due to
adverse events and other reasons in the AZT/3TC group in this open-label trial. In addition, 80% and
70% of subjects in the FTC+TDF group and the AZT/3TC group, respectively, achieved and
maintained HIV-1 RNA <50 copies/mL through Week 48 (64% and 56% through Week 144). The
mean increase from baseline in CD4+ cell count was 190 cells/mm3 in the FTC+TDF group and
158 cells/mm3 in the AZT/3TC group at Week 48 (312 and 271 cells/mm3 at Week 144).
Through 48 weeks, 7 subjects in the FTC+TDF group and 5 subjects in the AZT/3TC group
experienced a new CDC Class C event (10 and 6 subjects through 144 weeks).
14.3

Clinical Trial Results for HIV-1 PrEP: iPrEx

The iPrEx trial was a randomized, double-blind, placebo-controlled multinational study evaluating
TRUVADA in 2,499 HIV-seronegative men or transgender women who have sex with men and with
evidence of high-risk behavior for HIV-1 infection. Evidence of high-risk behavior included any one of
the following reported to have occurred up to six months prior to study screening: no condom use
during anal intercourse with an HIV-1 positive partner or a partner of unknown HIV status; anal
intercourse with more than 3 sex partners; exchange of money, gifts, shelter, or drugs for anal sex;
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sex with male partner and diagnosis of sexually transmitted infection; no consistent use of condoms
with sex partner known to be HIV-1 positive.
All subjects received monthly HIV-1 testing, risk-reduction counseling, condoms, and management of
sexually transmitted infections. Of the 2,499 enrolled subjects, 1,251 received TRUVADA and 1,248
received placebo. The mean age of subjects was 27 years; 5% were Asian, 9% Black, 18% White,
and 72% Hispanic/Latino.
Subjects were followed for 4,237 person-years. The primary outcome measure was the incidence of
documented HIV seroconversion. At the end of treatment, emergent HIV-1 seroconversion was
observed in 131 subjects, of which 48 occurred in the TRUVADA group and 83 occurred in the
placebo group, indicating a 42% (95% CI: 18–60%) reduction in risk. Risk reduction was found to be
higher (53%; 95% CI: 34–72%) among subjects who reported previous unprotected anal intercourse
(URAI) at screening (732 and 753 subjects reported URAI within the last 12 weeks at screening in the
TRUVADA and placebo groups, respectively). In a post-hoc case control study of plasma and
intracellular drug levels in about 10% of study subjects, risk reduction appeared to be greatest in
subjects with detectable intracellular tenofovir diphosphate concentrations. Efficacy was therefore
strongly correlated with adherence.
14.4

Clinical Trial Results for HIV-1 PrEP: Partners PrEP

The Partners PrEP trial was a randomized, double-blind, placebo-controlled 3-arm trial conducted in
4,758 HIV-1 serodiscordant heterosexual couples in Kenya and Uganda to evaluate the efficacy and
safety of TDF (N=1,589) and FTC/TDF (N=1,583) versus (parallel comparison) placebo (N=1,586) in
preventing HIV-1 acquisition by the uninfected partner.
All uninfected partner subjects received monthly HIV-1 testing, evaluation of adherence, assessment
of sexual behavior, and safety evaluations. Women were also tested monthly for pregnancy. Women
who became pregnant during the trial had study drug interrupted for the duration of the pregnancy
and while breastfeeding. The uninfected partner subjects were predominantly male (61–64% across
study drug groups) and had a mean age of 33–34 years.
Following 7,827 person-years of follow-up, 82 emergent HIV-1 seroconversions were reported, with
an overall observed seroincidence rate of 1.05 per 100 person-years. Of the 82 seroconversions, 13
and 52 occurred in partner subjects randomized to TRUVADA and placebo, respectively. Two of the
13 seroconversions in the TRUVADA arm and 3 of the 52 seroconversions in the placebo arm
occurred in women during treatment interruptions for pregnancy. The risk reduction for TRUVADA
relative to placebo was 75% (95% CI: 55–87%). In a post-hoc case control study of plasma drug
levels in about 10% of study subjects, risk reduction appeared to be greatest in subjects with
detectable plasma tenofovir concentrations. Efficacy was therefore strongly correlated with
adherence.
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HOW SUPPLIED/STORAGE AND HANDLING

TRUVADA tablets are available in bottles containing 30 tablets with child-resistant closure as follows:
•

100 mg of FTC and 150 mg of TDF (equivalent to 123 mg of tenofovir disoproxil) tablets are blue,
oval shaped, film coated, debossed with “GSI” on one side and with “703” on the other side (NDC
61958-0703-1).

•

133 mg of FTC and 200 mg of TDF (equivalent to 163 mg of tenofovir disoproxil) tablets are blue,
rectangular shaped, film coated, debossed with “GSI” on one side and with “704” on the other side
(NDC 61958-0704-1).
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•

167 mg of FTC and 250 mg of TDF (equivalent to 204 mg of tenofovir disoproxil) tablets are blue,
modified capsule shaped, film coated, debossed with “GSI” on one side and with “705” on the
other side (NDC 61958-0705-1).

•

200 mg of FTC and 300 mg of TDF (equivalent to 245 mg of tenofovir disoproxil) tablets are blue,
capsule shaped, film coated, debossed with “GILEAD” on one side and with “701” on the other
side (NDC 61958-0701-1).

Store at 25 C (77 F), excursions permitted to 15 C–30 C (59 F–86 F) (see USP Controlled
Room Temperature).
•

Keep container tightly closed

•

Dispense only in original container
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PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Important Information for Uninfected Individuals Taking TRUVADA for HIV-1 PrEP
Advise HIV-uninfected individuals about the following [see Warnings and Precautions (5.2)]:
•

The need to confirm that they are HIV-negative before starting to take TRUVADA to reduce the
risk of acquiring HIV-1.

•

That HIV-1 resistance substitutions may emerge in individuals with undetected HIV-1 infection
who are taking TRUVADA, because TRUVADA alone does not constitute a complete regimen for
HIV-1 treatment.

•

The importance of taking TRUVADA on a regular dosing schedule and strict adherence to the
recommended dosing schedule to reduce the risk of acquiring HIV-1. Uninfected individuals who
miss doses are at greater risk of acquiring HIV-1 than those who do not miss doses.

•

That TRUVADA does not prevent other sexually acquired infections and should only be used as
part of a complete prevention strategy including other prevention measures.

•

To use condoms consistently and correctly to lower the chances of sexual contact with any body
fluids such as semen, vaginal secretions, or blood.

•

The importance of knowing their HIV-1 status and the HIV-1 status of their partner(s).

•

The importance of virologic suppression in their partner(s) with HIV-1.

•

The need to get tested regularly for HIV-1 (at least every 3 months, or more frequently for some
individuals such as adolescents) and to ask their partner(s) to get tested as well.

•

To report any symptoms of acute HIV-1 infection (flu-like symptoms) to their healthcare provider
immediately.

•

That the signs and symptoms of acute infection include fever, headache, fatigue, arthralgia,
vomiting, myalgia, diarrhea, pharyngitis, rash, night sweats, and adenopathy (cervical and
inguinal).

•

To get tested for other sexually transmitted infections, such as syphilis, chlamydia, and gonorrhea,
that may facilitate HIV-1 transmission.

•

To assess their sexual risk behavior and get support to help reduce sexual risk behavior.
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Severe Acute Exacerbation of Hepatitis B in Patients Infected with HBV
Inform individuals that severe acute exacerbations of hepatitis B have been reported in patients who
are infected with HBV and have discontinued TRUVADA [see Warnings and Precautions (5.1)].
Advise HBV-infected individuals to not discontinue TRUVADA without first informing their healthcare
provider.
New Onset or Worsening Renal Impairment
Inform HIV-1 infected patients and uninfected individuals that renal impairment, including cases of
acute renal failure and Fanconi syndrome, has been reported in association with the use of TDF, a
component of TRUVADA. Advise patients to avoid TRUVADA with concurrent or recent use of a
nephrotoxic agent (e.g., high-dose or multiple NSAIDs) [see Warnings and Precautions (5.3)]. The
dosing interval of TRUVADA may need adjustment in HIV-1 infected patients with renal impairment.
TRUVADA for HIV-1 PrEP should not be used in HIV-1 uninfected individuals if estimated creatinine
clearance is less than 60 mL/min. If a decrease in estimated creatinine clearance is observed in
uninfected individuals while using TRUVADA for HIV-1 PrEP, evaluate potential causes and reassess potential risks and benefits of continued use [see Dosage and Administration (2.6)].
Immune Reconstitution Syndrome
Inform HIV-1 infected patients that in some patients with advanced HIV infection (AIDS), signs and
symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is
started. It is believed that these symptoms are due to an improvement in the body’s immune
response, enabling the body to fight infections that may have been present with no obvious
symptoms. Advise patients to inform their healthcare provider immediately of any symptoms of
infection [see Warnings and Precautions (5.4)].
Bone Loss and Mineralization Defects
Inform patients that decreases in bone mineral density have been observed with the use of TDF or
TRUVADA. Consider bone monitoring in patients and uninfected individuals who have a history of
pathologic bone fracture or at risk for osteopenia [see Warnings and Precautions (5.5)].
Lactic Acidosis and Severe Hepatomegaly
Inform HIV-1 infected patients and uninfected individuals that lactic acidosis and severe
hepatomegaly with steatosis, including fatal cases, have been reported. Treatment with TRUVADA
should be suspended in any person who develops clinical symptoms suggestive of lactic acidosis or
pronounced hepatotoxicity [see Warnings and Precautions (5.6)].
Drug Interactions
Advise individuals that TRUVADA may interact with many drugs; therefore, advise individuals to
report to their healthcare provider the use of any other medication, including other HIV drugs and
drugs for treatment of hepatitis C virus [see Warnings and Precautions (5.7) and Drug Interactions
(7)].
Dosage Recommendations for Treatment of HIV-1 Infection
Inform HIV-1 infected patients that it is important to take TRUVADA with other antiretroviral drugs for
the treatment of HIV-1 on a regular dosing schedule with or without food and to avoid missing doses
as it can result in development of resistance.
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Pregnancy Registry
Inform individuals using TRUVADA for HIV-1 treatment or HIV-1 PrEP that there is an antiretroviral
pregnancy registry to monitor fetal outcomes of pregnant women exposed to TRUVADA [see Use in
Specific Populations (8.1)].
Lactation
Instruct mothers not to breastfeed if they are taking TRUVADA for the treatment of HIV-1 infection or
if acute HIV-1 infection is suspected in a mother taking TRUVADA for HIV-1 PrEP because of the risk
of passing the HIV-1 virus to the baby. In HIV-uninfected women, the benefits and risks of TRUVADA
while breastfeeding should be evaluated, including the risk of HIV-1 acquisition due to medication
nonadherence and subsequent mother to child transmission [see Use in Specific Populations (8.2)].
TRUVADA, ATRIPLA, COMPLERA, EMTRIVA, EPCLUSA, HARVONI, SOVALDI, STRIBILD, and
VIREAD are trademarks of Gilead Sciences, Inc., or its related companies. All other trademarks
referenced herein are the property of their respective owners.
© 2020 Gilead Sciences, Inc. All rights reserved.
Manufactured for and distributed by:
Gilead Sciences, Inc.
Foster City, CA 94404
21752-GS-033

34

Medication Guide
TRUVADA® (tru-VAH-dah)
(emtricitabine and tenofovir disoproxil fumarate)
tablets
Read this Medication Guide before you start taking TRUVADA and each time you get a refill. There may be new
information. This information does not take the place of talking to your healthcare provider about your medical condition or
your treatment.
This Medication Guide provides information about two different ways that TRUVADA may be used. See the section
“What is TRUVADA?” for detailed information about how TRUVADA may be used.
What is the most important information I should know about TRUVADA?
TRUVADA can cause serious side effects, including:
• Worsening of hepatitis B virus infection (HBV). Your healthcare provider will test you for HBV before start or
when you start treatment with TRUVADA. If you have HBV infection and take TRUVADA, your HBV may get
worse (flare-up) if you stop taking TRUVADA. A “flare-up” is when your HBV infection suddenly returns in a
worse way than before.
• Do not run out of TRUVADA. Refill your prescription or talk to your healthcare provider before your TRUVADA is
all gone.
• Do not stop taking TRUVADA without first talking to your healthcare provider.
• If you stop taking TRUVADA, your healthcare provider will need to check your health often and do blood tests
regularly for several months to check your HBV infection, or give you a medicine to treat hepatitis B. Tell your
healthcare provider about any new or unusual symptoms you may have after you stop taking TRUVADA.
For more information about side effects, see the section “What are the possible side effects of TRUVADA?”.
Other important information for people who take TRUVADA to help reduce their risk of getting human
immunodeficiency virus-1 (HIV-1) infection, also called pre-exposure prophylaxis or “PrEP”:
Before taking TRUVADA to reduce your risk of getting HIV-1:
• You must be HIV-1 negative to start TRUVADA. You must get tested to make sure that you do not already
have HIV-1 infection.
• Do not take TRUVADA for HIV-1 PrEP unless you are confirmed to be HIV-1 negative.
• Some HIV-1 tests can miss HIV-1 infection in a person who has recently become infected. If you have flu-like
symptoms, you could have recently become infected with HIV-1. Tell your healthcare provider if you had a flu-like
illness within the last month before starting TRUVADA or at any time while taking TRUVADA. Symptoms of new HIV1 infection include:
• tiredness
• vomiting or diarrhea
• fever
• rash
• joint or muscle aches
• night sweats
• headache
• enlarged lymph nodes in the neck or groin
• sore throat
While you are taking TRUVADA for HIV-1 PrEP:
• TRUVADA does not prevent other sexually transmitted infections (STIs). Practice safer sex by using a latex or
polyurethane condom to reduce the risk of getting STIs.
• You must stay HIV-negative to keep taking TRUVADA for HIV-1 PrEP.
•
•

•
•
•
•
•

Know your HIV-1 status and the HIV-1 status of your partners.
Ask your partners with HIV-1 if they are taking anti-HIV-1 medicines and have an undetectable viral load. An
undetectable viral load is when the amount of virus in the blood is too low to be measured in a lab test. To
maintain an undetectable viral load, your partners must keep taking HIV-1 medicines every day. Your risk of
getting HIV-1 is lower if your partners with HIV-1 are taking effective treatment.
Get tested for HIV-1 at least every 3 months or when your healthcare provider tells you.
Get tested for other STIs such as syphilis, chlamydia, and gonorrhea. These infections make it easier for HIV-1 to
infect you.
If you think you were exposed to HIV-1, tell your healthcare provider right away. They may want to do more tests
to be sure you are still HIV-1 negative.
Get information and support to help reduce sexual risk behaviors.
Do not miss any doses of TRUVADA. Missing doses increases your risk of getting HIV-1 infection.
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•

If you do become HIV-1 positive, you need more medicine than TRUVADA alone to treat HIV-1. TRUVADA by itself is
not a complete treatment for HIV-1.
If you have HIV-1 and take only TRUVADA, over time your HIV-1 may become harder to treat.
What is TRUVADA?
TRUVADA is a prescription medicine that may be used in two different ways. TRUVADA is used:
• to treat HIV-1 infection when used with other anti-HIV-1 medicines in adults and children who weigh at least 37
pounds (at least 17 kg).
• for HIV-1 PrEP to reduce the risk of getting HIV-1 infection in adults and adolescents who weigh at least 77 pounds
(at least 35 kg).
HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS).
TRUVADA contains the prescription medicines emtricitabine and tenofovir disoproxil fumarate.
It is not known if TRUVADA for treatment of HIV-1 infection is safe and effective in children who weigh less than 37
pounds (17 kg).
It is not known if TRUVADA is safe and effective in reducing the risk of HIV-1 infection in people who weigh less than 77
pounds (35 kg).
For people taking TRUVADA for HIV-1 PrEP:
Do not take TRUVADA for HIV-1 PrEP if:
• you already have HIV-1 infection. If you are HIV-1 positive, you need to take other medicines with TRUVADA to
treat HIV-1. TRUVADA by itself is not a complete treatment for HIV-1.
• you do not know your HIV-1 infection status. You may already be HIV-1 positive. You need to take other HIV-1
medicines with TRUVADA to treat HIV-1.
TRUVADA can only help reduce your risk of getting HIV-1 before you are infected.
What should I tell my healthcare provider before taking TRUVADA?
Before taking TRUVADA, tell your healthcare provider about all of your medical conditions, including if you:
• have liver problems, including HBV infection
• have kidney problems or receive kidney dialysis treatment
• have bone problems
• are pregnant or plan to become pregnant. It is not known if TRUVADA can harm your unborn baby. Tell your
healthcare provider if you become pregnant during treatment with TRUVADA.
Pregnancy Registry: There is a pregnancy registry for people who take TRUVADA during pregnancy. The purpose
of this registry is to collect information about the health of you and your baby. Talk with your healthcare provider about
how you can take part in this registry.
• are breastfeeding or plan to breastfeed. TRUVADA can pass to your baby in your breast milk.
• Do not breastfeed if you have HIV-1 or if you think you have recently become infected with HIV-1 because of the
risk of passing HIV-1 to your baby.
• If you take TRUVADA for HIV-1 PrEP, talk with your healthcare provider about the best way to feed your baby.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter
medicines, vitamins, and herbal supplements.
Some medicines may interact with TRUVADA. Keep a list of your medicines and show it to your healthcare provider and
pharmacist when you get a new medicine.
• You can ask your healthcare provider or pharmacist for a list of medicines that interact with TRUVADA.
• Do not start a new medicine without telling your healthcare provider. Your healthcare provider can tell you if it is
safe to take TRUVADA with other medicines.
How should I take TRUVADA?
• Take TRUVADA exactly as your healthcare provider tells you to take it. If you take TRUVADA to treat HIV-1 infection,
you need to take other HIV-1 medicines. Your healthcare provider will tell you what medicines to take and how to take
them.
• Take TRUVADA 1 time each day with or without food.
• Children who take TRUVADA are prescribed a lower strength tablet than adults. Children should swallow the
TRUVADA tablet. Tell your healthcare provider if your child cannot swallow the tablet, because they may need a
different HIV-1 medicine.
• Your healthcare provider will change the dose of TRUVADA as needed based on your child’s weight.
• Do not change your dose or stop taking TRUVADA without first talking with your healthcare provider. Stay under a
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healthcare provider’s care when taking TRUVADA. Do not miss a dose of TRUVADA.
• If you take too much TRUVADA, call your healthcare provider or go to the nearest hospital emergency room right
away.
• When your TRUVADA supply starts to run low, get more from your healthcare provider or pharmacy.
o If you are taking TRUVADA for treatment of HIV-1, the amount of virus in your blood may increase if the
medicine is stopped for even a short time. The virus may develop resistance to TRUVADA and become
harder to treat.
o If you are taking TRUVADA for HIV-1 PrEP, missing doses increases your risk of getting HIV-1 infection.
What are the possible side effects of TRUVADA?
TRUVADA may cause serious side effects, including:
• See “What is the most important information I should know about TRUVADA?”
• New or worse kidney problems, including kidney failure. Your healthcare provider should do blood and urine
tests to check your kidneys before you start and during treatment with TRUVADA. Your healthcare provider may tell
you to take TRUVADA less often, or to stop taking TRUVADA if you get new or worse kidney problems.
• Changes in your immune system (Immune Reconstitution Syndrome) can happen when taking medicines to
treat HIV-1 infection. Your immune system may get stronger and begin to fight infections that have been hidden in
your body for a long time. Tell your healthcare provider right away if you start having any new symptoms after starting
your HIV-1 medicine.
•
•

•

Bone problems can happen in some people who take TRUVADA. Bone problems include bone pain, or softening or
thinning of bones, which may lead to fractures. Your healthcare provider may need to do tests to check your bones.
Too much lactic acid in your blood (lactic acidosis). Too much lactic acid is a serious but rare medical emergency
that can lead to death. Tell your healthcare provider right away if you get these symptoms: weakness or being more
tired than usual, unusual muscle pain, being short of breath or fast breathing, stomach pain with nausea and vomiting,
cold or blue hands and feet, feel dizzy or lightheaded, or a fast or abnormal heartbeat.
Severe liver problems. In rare cases, severe liver problems can happen that can lead to death. Tell your healthcare
provider right away if you get these symptoms: skin or the white part of your eyes turns yellow, dark “tea-colored”
urine, light-colored stools, loss of appetite for several days or longer, nausea, or stomach-area pain.

The most common side effects of TRUVADA for treatment of HIV-1 include:
• diarrhea
• depression
• nausea
• problems sleeping
• tiredness
• abnormal dreams
• headache
• rash
• dizziness
Common side effects in people who take TRUVADA for HIV-1 PrEP include:
• headache
• stomach-area (abdomen) pain
• decreased weight
These are not all the possible side effects of TRUVADA.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store TRUVADA?
• Store TRUVADA at room temperature between 68F to 77F (20C to 25C).
• Keep TRUVADA in its original container.
• Keep the container tightly closed.
• Do not use TRUVADA if seal over bottle opening is broken or missing.
Keep TRUVADA and all other medicines out of reach of children.
General information about TRUVADA.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TRUVADA
for a condition for which it was not prescribed. Do not give TRUVADA to other people, even if they have the same
symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about
TRUVADA that is written for health professionals.
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What are the ingredients in TRUVADA?
Active ingredients: emtricitabine and tenofovir disoproxil fumarate.
Inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and
pregelatinized starch (gluten free). The 200 mg/300 mg strength tablets are coated with Opadry II Blue Y-30-10701, which
contains FD&C Blue #2 aluminum lake, hypromellose 2910, lactose monohydrate, titanium dioxide, and triacetin. The 167
mg/250 mg, 133 mg/200 mg, and 100 mg/150 mg strength tablets are coated with Opadry II Blue, which contains FD&C
Blue #2 aluminum lake, hypromellose 2910, lactose monohydrate, titanium dioxide, and triacetin.
Manufactured for and distributed by:
Gilead Sciences, Inc.
Foster City, CA 94404
TRUVADA is a trademark of Gilead Sciences, Inc., or its related companies.
© 2020 Gilead Sciences, Inc. All rights reserved.
21752-GS-033
For more information, call 1-800-445-3235 or go to www.TRUVADA.com.
This Medication Guide has been approved by the U.S. Food and Drug Administration.
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PACKAGE LEAFLET: INFORMATION FOR THE USER
Zinnia F *
ethinylestradiol/levonorgestrel 30µg/150 µg coated tablets
Read all of this leaflet carefully before you start taking this medicine because it contains
important information for you.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor, health care provider or pharmacist
•
This medicine has been prescribed for you only. Do not pass it on to others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any side effects, talk to your doctor, health care provider or pharmacist. This includes
any possible side effects not listed in this leaflet.
What is in this leaflet:
1.
2.
3.
4.
5.
6.
1.

What Zinnia F is and what it is used for
What you need to know before you take Zinnia F
How to take Zinnia F
Possible side effects
How to store Zinnia F
Contents of the pack and other information
WHAT ZINNIA F IS AND WHAT IT IS USED FOR

Zinnia F is a low dose combined contraceptive pill that protects against pregnancy (here generally
designated as ‘Pill’).
Zinnia F contains 28 tablets per card.
The active tablets (21 white tablets) contain a small amount of two female sex hormones, a
progestogen (levonorgestrel) and an estrogen (ethinylestradiol). The active tablet is generally
designated as the “Pill”.
The other tablets (7 brown tablets) are hormone-free.
2.

WHAT YOU NEED TO KNOW BEFORE YOU TAKE ZINNIA F

2.1

Do not take Zinnia F:

-

-

if you are hypersensitive (allergic) to ethinylestradiol, levonorgestrel or any of the other
components of Zinnia F,
if you now have or have a history of venous blood clots (in deep veins or in lungs), whether you
are on anticoagulant therapy or not,
if you now have or have a history of arterial blood clots (e.g. heart attack) or diseases associated
with the early stages of such blood clots in the arteries (such as tightness in the chest, so-called
Angina pectoris, or sudden visual disturbances or muscle paralysis),
if you have a known tendency to form blood clots or any other condition associated with clots,
such as disease of heart valves or heart rhythm problems),
if you have lupus, a disorder of the immunes system,

*

Trade names are not prequalified by WHO. This is the national medicines regulatory authority’s (NMRA)
responsibility. Throughout this WHOPAR the proprietary name is given as an example only.
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if you have many risk factors for artery disease (such as older age, smoking, diabetes and high
blood pressure),
if you have had a stroke,
if you smoke (also see 2.2.3 ‘The “Pill” and vascular disease’),
if you suffer from high blood pressure above 160/100 mm Hg and it has not been satisfactorily
treated,
if you suffer from sugar diabetes (Diabetes mellitus) and your blood vessels have already been
damaged as a result,
if you have a history of migraines, which are accompanied by sensory, perceptual and/or motor
disturbances (so-called aura),
if you now have or have a history of pancreatic inflammation,
if you now have or have a history of liver disorder, as long as liver function tests have not
returned to normal,
if you have acute hepatitis (liver inflammation) or a hepatitis flare: combined oral
contraceptives should not be started during these; continuing use for those already taking
combined oral contraceptives is usually possible.
if you now have or have a history of liver tumors (benign or malignant),
if you are now suspected of having or have a history of sex-steroid influenced cancer (e.g. of
lining of the uterus or the breasts),
if you have undiagnosed vaginal bleeding,
if you miss menstruation, the cause of which has not been found.

Discontinue use immediately, if one of the above-mentioned diseases or conditions appears for the
first time while taking Zinnia F.
2.2

Warnings and precautions

2.2.1

Stop taking Zinnia F immediately (in addition to conditions specified in section 2.1)

-

-

-

if you suspect or know that you are pregnant,
if there are signs that you have a blood clot, such as sudden sensation, perception or movement
problems,
if your blood pressure constantly rises to values above 140/90 mmHg (you can think of starting
to take the ‘Pill’ again, as soon as your blood pressure values have returned to normal through
antihypertensive therapy),
if surgery is planned (at least 4 weeks in advance) and/or during longer periods of
immobilization (also see 2.2.3 ‘The “Pill” and vascular disease’). You can think of starting to
take the “Pill” again at least two weeks after complete remobilization.
if migraine appears for the first time or worsens,
if headaches occur unusually frequently, persistently or in unusual severity,
if severe upper abdominal pain or swelling occurs,
if your skin and the whites of your eyes turn yellow, your urine turns brown and your stool very
light in color (so-called jaundice), or if your skin itches over your entire body,
if you suffer from sugar diabetes (Diabetes mellitus) and your blood sugar count is suddenly
increased,
if you suffer from a condition called porphyria, occurring in episodes, and which recurs while
using Zinnia F.

2.2.2 You require special medical monitoring
-

if you smoke (especially if you are over age 35 and you smoke more than 15 cigarettes per day),
if you are 40 years of age or older,
if you are overweight,
if you have a heart or kidney condition,
if you are inclined to have inflamed superficial veins (phlebitis) or pronounced varicose veins,
if you have circulatory problems in your hands and feet,
if your blood pressure has been measured to be over 140/90 mmHg,
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if you suffer from migraine,
if you suffer from depression,
if you have epilepsy,
if you have sugar diabetes (Diabetes mellitus) or if your body’s ability to use glucose is reduced,
(decreased glucose tolerance). It may be that the required dose of the drugs used to treat your
diabetes will change while using Zinnia F.
if you are known to have a disturbed lipid (fat) metabolism,
if you are known to have sickle cell disease,
if you have a movement disorder called chorea,
if you have had a liver disorder,
if you are known to have a gallbladder disorder,
if you suffer from a benign tumor in the muscle layer of the uterus (uterine myoma),
if you suffer from a chronic inflammatory bowel disease (Crohn's disease, ulcerative colitis),
if you have a certain manifestation of deafness (otosclerosis),
in the event of prolonged immobilization, e.g. following accidents (see 2.2.1),
if you suffer from a certain disorder of the immune system, the so-called lupus,
if you are known to have haemolytic-uremic syndrome (a disorder of blood and kidneys).

2.2.3 The ‘Pill’ and blood vessel disease
Using the ‘Pill’ gives an increased risk of blood clots. The additional risk is at its highest during the
first year a woman ever uses the ‘Pill’. This increased risk when using the ‘Pill’ is lower than the risk
of clots developing during pregnancy, which is estimated at 60 cases per 100,000 pregnancies. In 1 2% of the cases, such clots result in death. The frequency of a clot, caused by ‘Pills’ containing the
amounts in Zinnia F is about 20 cases in every 100,000 women who have been using the ‘Pill’ for one
year.
In rare cases, clots can also occur in an artery, such as in heart vessels or the arteries that supply the
brain, resulting in a heart attack or stroke. In very rare cases, clots can also occur in the blood vessels
of the liver, intestines, kidneys or eyes.
The following signs can point to a clot. If you notice any of these signs in yourself, stop taking the
tablets immediately and see your doctor, at once:
unusual pain or swelling in a leg,
pain and tightness in the chest, possibly radiating into the left arm,
sudden difficulty in breathing,
heavy cough without a clear cause,
unusual, strong or persistent headaches,
sudden partial or complete loss of vision,
seeing double,
indistinct speech, problems with speaking or loss of speech,
dizziness,
collapse, possibly in connection with an epileptic seizure,
sudden weakness or numbness on one side of the body or in one part of the body,
problems with movement,
severe abdominal pain.
The risk of clots increases:
with increasing age,
with a history of blood clots in close family members (parents or siblings) at a relatively early
age,
with prolonged immobilization, major surgery, surgery to the legs, or major trauma. In these
situations it is advisable to discontinue use of the ‘Pill’ (at least four weeks in advance of
elective surgery as well as in the event of prolonged immobilization) and not to resume until
two weeks after complete remobilization. If Zinnia F was not discontinued in time, a prevention
for clots should be considered.
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if you are clearly overweight (Body Mass Index over 30 kg/m2),
in the first three to four weeks following delivery or a miscarriage in the second trimester of
pregnancy.

The risk of arterial occlusion increases with:
smoking. With heavier smoking and increasing age, the risk further increases. It is advisable not
to smoke, especially if you are over 35 and using hormones to prevent pregnancy. If you cannot
stop smoking, you are advised to use other methods of contraception, especially if there are
other risk factors.
increasing age,
the occurrence of blood clots in close family members (parents or siblings) at an early age,
disturbances in lipid (fat) metabolism,
high blood pressure,
sugar diabetes (Diabetes mellitus),
heart conditions (such as valve disease, irregular beats),
obesity (body mass index over 30 kg/m2),
migraine, especially migraine with aura.
-

Further diseases with possible blood vessel involvement include lupus, (an immune system disorder)
haemolytic-uremic syndrome (a blood disorder causing kidney damage) and chronic inflammatory
bowel disease (Crohn's disease and ulcerative colitis).
The presence of a severe or multiple risk factor(s) for vein or artery clots may also constitute a reason
not to use Zinnia F.
The increased risk of blood clots just after giving birth must be considered.
2.2.4 The ‘Pill’ and cancer
Some studies have indicated that long-term use of combined oral contraceptives represents a risk
factor with respect to developing cervical cancer in women, whose cervix is infected with a certain
sexually transmitted virus (human papillomavirus). It has not yet been established, however, to which
extent this finding is attributable to other factors (e.g., differences in the number of sex partners or in
the use of barrier contraceptives).
There is a slightly increased risk of having breast cancer diagnosed in women who are currently using
the ‘Pill’ as compared to women of the same age who do not use the ‘Pill’ for contraception. This
excess risk gradually disappears after cessation of the ‘Pill’, and during the course of 10 years, there is
no difference between previous ‘Pill’ users and other women of the same age. Because breast cancer is
rare in women under 40 years of age, the excess number of cases in current and recent users of the
‘Pill’ is small in relation to the overall risk of breast cancer.
In very rare cases, benign, but nonetheless dangerous, liver tumors can occur, which can rupture
causing severe internal bleeding. In case of severe upper abdominal pain, please contact your doctor
immediately. Studies have suggested an increased risk of developing liver-cell cancer with long-term
use of the ‘Pill’; this type of cancer is, however, very rare.
2.2.5 Other conditions
High blood pressure
An increase in blood pressure has been reported in women taking the ‘Pill’. This occurs more
frequently in older users and with continued use. The frequency of high blood pressure increases with
the content of the progestogen. If you have already contracted any disorders due to high blood
pressure, or if you suffer from certain kidney disorders, it is advisable for you to use another method
of contraception (see also 2.1 ‘Do not take Zinnia F, 2.2.1 ‘Stop taking Zinnia F immediately’ and
2.2.2 ‘You require special medical monitoring’).
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Pigmentation spots
Yellowish-brown pigment spots may occasionally occur, especially in women with a history of
chloasma gravidarum. It is therefore advisable for women with this tendency not to expose themselves
directly to the sun or ultraviolet radiation (e.g. on sunbeds) while taking the ‘Pill’.
Hereditary angioedema
If you suffer from hereditary angioedema (a severe allergic condition), medicinal products containing
estrogens, may worsen the condition. You should immediately consult your doctor if you notice you
have symptoms such as swelling of the face, tongue and/or throat and/or difficulty swallowing or skin
rash combined with breathing problems.
Irregular bleeding
With all ‘Pills’, irregular bleeding (spotting or breakthrough bleeding) may occur, especially during
the first months of use. If this irregular bleeding still occurs after three months or reappears after
several months of regular cycles, please see your doctor.
It is possible that in some women withdrawal bleeding may not occur during the hormone free period
(brown tablets). If you have taken Zinnia F according to the directions described in Section 3 ‘How to
take Zinnia F ’, it is unlikely that you are pregnant. However, if you have not taken the 'Pill' according
to these directions prior to the first missed withdrawal bleed or if two withdrawal bleeds are missed,
pregnancy must be ruled out before Zinnia F use is continued.
After discontinuing the ‘Pill’, it can take some time to return to a normal cycle.
2.2.6 Reduced efficacy
The contraceptive effect can be reduced by forgetting to take the 'Pill', vomiting, gastrointestinal
disturbances with diarrhoea or by some other medicines taken at the same time.
If Zinnia F and products containing St. John’s wort are taken at the same time, it is advisable to use an
additional barrier contraceptive (see Section 2.3, “Other medicines and Zinnia F”).
2.2.7 Medical consultation / examination
Before you use Zinnia F, your doctor will ask you detailed questions about your medical history and
that of your close relatives. A thorough general medical checkup and a gynaecological examination,
including an examination of the breast and a cervical smear, will be conducted. Pregnancy has to be
ruled out. These examinations should be repeated regularly while you are taking the ‘Pill’. Please tell
your doctor whether you smoke and whether you are taking other medicines.
Zinnia F does not protect you against HIV infection or other sexually transmitted diseases. Among
other safe sex practices consistent and correct use of condoms, male or female, is critical for
prevention of HIV transmission.
Folic-acid deficiency can interfere with the development of the brain and spinal cord (neural tube
defects) in the unborn child. If you stop taking Zinnia F because you want to become pregnant, you are
advised to adhere to a diet rich in folic acid (vegetables, fruit, wholegrain products), and to take an
additional 0.4 milligrams of folic acid daily. It should be taken four weeks prior to the planned
conception and continued up to week 12 of pregnancy. Any woman, who has already been pregnant
with a child who had a neural tube (spinal cord) defect, should take 4 milligrams or 5 milligrams of
folic acid daily over the same period. You are advised to heed the contraindications and warnings
contained in the patient information leaflet of folic acid preparations.
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Other medicines and Zinnia F

Talk to your doctor, health care provider or pharmacist if you are taking or have recently taken any
other medicines, even those not prescribed.
2.3.1 Interactions between Zinnia F and other medicinal products can cause it to lose its
contraceptive efficacy and/or can result in breakthrough bleeding.
The following medicinal products can reduce the effect of Zinnia F:
drugs, that increase intestinal motility (e.g. metoclopramide),
drugs used in treating epilepsy such as phenytoin, barbiturates, barbexaclone, primidone,
carbamazepine, oxcarbazepine, topiramate and felbamate,
some antibiotics for the treatment of tuberculosis (e.g. rifampicin, rifabutin), certain others
against bacterial infections (e.g. ampicillin, tetracycline) or fungal infections (e.g. griseofulvin),
certain drugs for the treatment of HIV infection (e.g. ritonavir, nevirapine, efavirenz),
modafinil (agent for the treatment of narcolepsy, a nervous system disorder),
herbal products that contain St. John's wort (Hypericum perforatum).
-

If you are being treated with any of the drugs specified above, you are advised to use a barrier
contraceptive (e.g. condom) in addition to Zinnia F. You are advised not only to use these additional
methods of contraception during concomitant use with some of the drugs specified above, but for
another seven to 28 days, depending upon the drug. If you have questions, ask your doctor or
pharmacist.
If the use of these drugs extends beyond the last active tablet in the current blister pack, then you
should skip the seven hormone free tablets and start taking the active tablets from the next pack of
Zinnia F.
If long-term treatment with any of the drugs specified above is necessary, it is preferable to choose a
non-hormonal method of contraception.
2.3.2 Interactions between Zinnia F and other drugs can also cause more numerous and more
pronounced side effects.
The following medicinal products can impair the tolerance of Zinnia F:
paracetamol (acetaminophen), a drug to relieve pain and fever),
ascorbic acid (vitamin C)
atorvastatin (a drug for lowering blood fat),
troleandomycin (an antibiotic),
imidazole, antifungal drugs (such as fluconazole),
indinavir (an HIV drug).
-

2.3.3 Zinnia F and other ‘Pills’ can also affect the metabolism of other drugs.
Zinnia F can impair the efficacy or tolerability of the following drugs:
cyclosporine (drug used to suppress the immune system),
theophylline (a drug used for the treatment of asthma),
glucocorticoids (e.g. cortisone),
benzodiazepines (tranquilizers, such as diazepam, lorazepam),
lamotrigine (a drug used for the treatment of epilepsy),
clofibrate (a drug for lowering the blood fat),
paracetamol (acetaminophen, a drug to relieve pain and fever),
morphine (a narcotic pain killer).
Please, also follow the patient information leaflets of the other prescribed products.
If you are diabetic (if you have sugar diabetes) your required dose of blood-sugar lowering medicine
(e.g. insulin) can change.
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2.3.4 Laboratory tests
Use of the ‘Pill’ may influence the results of certain laboratory tests, including the results of liver, thyroid, adrenal gland and kidney function testing, as well as certain blood protein levels, e.g., proteins,
which affect blood fat usage, carbohydrate usage, and clotting.
2.4.

Pregnancy and breast-feeding.

Zinnia F should not be used during pregnancy. You should not be pregnant when starting Zinnia F. If
pregnancy occurs during treatment with Zinnia F, further intake should be stopped, and you should see
your doctor.
Do not use Zinnia F during the first 6 months of breast-feeding, since milk production may be reduced
and small quantities of the active substance can pass into breast milk. You should use a non-hormonal
method of contraception, if you are breastfeeding.
Ask your doctor or pharmacist for advice before taking any medicine.
2.5

Driving and using machines

No special precautionary measures are necessary.
2.6

Zinnia F contains lactose and sucrose.

Each active tablet of this medicinal product contains lactose and sucrose (sugar) while the hormone
free tablets contains sucrose. If you have been told by your doctor that you have intolerance to some
sugars, contact your doctor before taking this medicinal product.
2.7

Zinnia F contains methylparaben and propylparaben.

Each hormone free tablet contains methylparaben and propylparaben. These may cause allergic
reactions (possibly delayed).
3.

HOW TO TAKE ZINNIA F

Always take Zinnia F exactly as your doctor or health care provider told you. You should check with
your doctor, health care provider or pharmacist if you are not sure.
The usual dose is: One tablet of Zinnia F daily.
3.1

How to take Zinnia F

Each blister card contains 21 active tablets (white) and 7 hormone-free tablets (brown). Take
one tablet daily until the blister card is empty. Start with the next blister pack on the following day
without any pause.
You should take the ‘Pill’ whole (do not chew) with some liquid, if necessary.
You must take the ‘Pill’ each day at about the same time in the sequence indicated on the blister pack
for 28 consecutive days. After you have taken all the 21 active tablets (white), take the hormone free
tablets (brown) the next seven days. Generally the withdrawal bleeding will start during these 7 days.
This usually begins 2 to 3 days after taking the last active tablet and can persist until you start taking
tablets from the next blister pack.
3.2

When to start taking Zinnia F

If you did not take a contraceptive ‘Pill’ last month:
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Start with the white active tablets in your blister card. You may start taking Zinnia F on day 1 of your
natural cycle, i.e. the first day of your menstrual bleeding. If you begin taking the tablets on any other
day, an additional barrier contraceptive should be used during the first seven days of taking the ‘Pill’.
If you are switching to Zinnia F from another ‘Pill’ (with two hormonal active substances), or from a
vaginal ring or a patch:
if you have been taking a ‘Pill’ with a tablet-free interval once a month following your last ‘Pill’
containing an active substance, start taking Zinnia F on the day following your tablet-free
interval.
if you have been taking a ‘Pill’ that comes in a calendar pack containing placebo tablets along
with the ‘Pills’ containing active substances, start taking Zinnia F on the day following your last
placebo.
if you have been using a vaginal ring or a patch, start taking Zinnia F on the day following the
usual ring-free, or patch-free interval.
If you are switching to Zinnia F from a ‘Pill’, that contains only one hormone (progestogen), a socalled mini pill:
You can discontinue the ‘mini pill’ on any day. Start taking Zinnia F on the following day. During the
first seven days, you should use an additional barrier contraceptive (e.g. condom).
If you are switching to Zinnia F from an injectable product (so-called ‘three-month injection’), from
an implant or an intrauterine device:
Start taking Zinnia F at the time you would normally get the next injection or on the day the implant or
intrauterine device is removed. Use an additional barrier contraceptive during the first seven days.
If you have just had a baby and are not breastfeeding:
Do not start taking the product any earlier than 21days after delivery. A longer period of up to 42 days
should be allowed in any woman having risk factors for blood clots (See section 2.2.3, The “Pill” and
blood vessel disease).
If you begin to take the tablets later, you should use an additional barrier contraceptive during the first
seven days. If you have already had sexual intercourse, pregnancy must be ruled out, or you must wait
for your first menstrual bleed before starting to take Zinnia F. See also section 2.4 ‘Pregnancy and
breastfeeding’.
If you have just had a miscarriage or an abortion:
You may take Zinnia F immediately.
3.3

Duration of use

Zinnia F can be taken for as long as a hormonal method of contraception is desired and there are no
significant health risks (see 2.1 ‘Do not take Zinnia F’ and 2.2.1 ‘Stop taking Zinnia F immediately’).
Regarding check-ups see 2.2.7 ‘Medical consultation / examination.’
3.4

If you take more Zinnia F than you should

Possible signs of an overdose are nausea, vomiting (usually after 12 to 24 hours, sometimes continuing
for several days), chest tightness, giddiness, abdominal pain, sleepiness / tiredness, vaginal bleeding. If
you have taken large quantities, consult a doctor so that the symptoms can be treated.
3.5


If you forget to take Zinnia F
If you are less than 12 hours late in taking one active tablet, the contraceptive effect of Zinnia F is
not reduced. You should take the missed tablet as soon as possible, and then take the subsequent
‘Pills’ at your usual time.
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If you are more than 12 hours late in taking one of the active tablets, the contraceptive effect is no
longer fully ensured. If no bleeding appears during the seven day hormone free period (brown
tablets) after having taken the 21 white active tablets , you could be pregnant. In this case, you
must see your doctor before starting a new blister pack.

There are generally two things to bear in mind:
1.
You must never stop taking the ‘Pill’ for more than seven days.
2.
In order to build up sufficient contraceptive protection, you should take the ‘Pill’ without
interruption for seven days.
You missed one ‘Pill’ in week 1:
Take the missed ‘Pill’ as soon as possible, even if this means taking two ‘Pills’ at the same time. Then
continue taking the tablets as usual. However, an additional barrier contraceptive (e.g. condom) should
be used for the next seven days. If you had sexual intercourse in the week prior to the missed ‘Pill’,
you are at risk of being pregnant. The likelihood of becoming pregnant is greater, the closer the missed
‘Pill’ is to the period when the brown hormone-free tablets were taken.
You missed one ‘Pill’ in week 2:
Take the missed ‘Pill’ as soon as possible, even if this means taking two ‘Pills’ at the same time. Then,
take the subsequent ‘Pills’ again at your usual time. Provided you took Zinnia F regularly on the seven
days preceding the missed ‘Pill’, then the contraceptive effect of the ‘Pill’ is ensured, and you do not
have to use any additional contraceptive measures. If this was not the case or if you missed more than
one ‘Pill’, then you are advised to use an additional barrier contraceptive (e.g. condom) for seven days.
You missed one ‘Pill’ in week 3:
Due to the upcoming seven-day hormone free tablet interval, contraceptive protection is no longer
fully assured. You can, however, sustain the contraceptive effect by adjusting your tablet-taking
schedule. By following one of the two procedures described below, it is not necessary to use additional
contraceptive measures, although this is only true if you took the tablets correctly on the seven days
preceding the first missed ‘Pill.’(If this is not the case, you should proceed as described above, “You
Missed one ‘Pill’ in week 1.” You should also use an additional barrier contraceptive (e.g. condom)
for the next seven days.
You can choose between two options:
1.

Take the missed ‘Pill’ as soon as possible, even if this means taking two ‘Pills’ at the same time.
Then, take the subsequent ‘Pills’ again at your usual time. Skip the seven brown hormone free
tablets and start taking “Pills”(white tablets) from the next blister pack right away. Withdrawal
bleeding will probably not occur until you have used up the active tablets in the second blister
pack, but there may be spotting and breakthrough bleeding while you are taking the second
pack.

Or
2.

You can immediately start the brown hormone free tablets (you also have to count the day you
missed the ‘Pill’ as if it were a hormone-free pill day). Start taking the tablets from the next
blister pack right away. If you wish to start taking the next blister pack on your accustomed day
of the week, you can take fewer hormone free tablets accordingly.
Please bear in mind that the maximum time between your last white tablet from the previous
blister and the first white tablet of the current blister should not exceed 7 days.

If you have missed more than one active tablet from the current blister pack:
If you miss more than one active tablets of Zinnia F from the current blister pack, contraceptive
protection is no longer certain.
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The likelihood of becoming pregnant is all the greater, the more ‘Pills’ you missed and the closer this
is to the period when the brown tablets were taken. It is advisable for you to use an additional barrier
contraceptive (e.g. condom) until your next regular withdrawal bleed. If no bleeding occurs during the
hormone free period (brown tablets) , you could be pregnant. In this event, you must see your doctor
before starting a new blister pack.
What has to be considered if you suffer from vomiting or diarrhoea
If you have digestive problems, such as vomiting or diarrhoea, occurring within the first four hours
after taking the white active tablets, the active substances might not have been completely absorbed. In
such cases, follow the instructions that apply to when you miss a ‘Pill’ and you notice it within 12
hours. If you do not wish to deviate from your tablet-taking rhythm, you will have to take the
replacement tablet from another blister pack. If your gastrointestinal complaints continue for several
days or recur, you or your partner should use an additional barrier contraceptive (e.g. diaphragm,
condom), and you should inform your doctor.
What has to be considered if you wish to change the timing of the withdrawal bleed
To postpone withdrawal bleeding, you should continue taking the active tablets from the next pack of
Zinnia F right away, skipping the brown tablets. Withdrawal bleeding can be delayed for as long as
desired by taking the tablets continuously, though evidence for this is limited beyond 2 years. If you
do this, you may experience increased breakthrough bleeding or spotting. Following a subsequent
regular seven-day use of the brown tablets, you can continue to take the white active tablets as usual.
3.6

If you stop taking Zinnia F

If you wish to stop taking Zinnia F, ask your doctor or pharmacist.
If you have any further questions on the use of this medicine, ask your doctor, health care provider or
pharmacist.
4.

POSSIBLE SIDE EFFECTS

Like all medicines, Zinnia F can cause side effects, although not everybody gets them.
The most common side effects, which may affect more than 1 in 10 people associated with taking the
‘Pill’ containing the active substances, ethinylestradiol and levonorgestrel, are headaches (including
migraine), spotting and intermenstrual bleeding.
Frequency of side effects
System Organ
Class

Infections

Immune system
disorders

Common

Uncommon

Rare

Very rare

(may affect up to 1 in
10 people)

(may affect up
to 1 in 100
people)

(may affect up to
1 in 1,000
people)

(may affect up
to 1 in 10,000
people)

hives

allergic reactions

painful
swelling of the
skin and
mucous
membrane
(angioedema),
very severe

vaginal inflammation,
including mycosis
(Candidiasis)
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Frequency of side effects
System Organ
Class

Common

Uncommon

Rare

Very rare

(may affect up to 1 in
10 people)

(may affect up
to 1 in 100
people)

(may affect up to
1 in 1,000
people)

(may affect up
to 1 in 10,000
people)
allergic
reactions with
breathing and
circulatory
symptoms

Metabolism and
nutrition
disorders

changes of
appetite
(increase or
decrease)

Psychiatric
disorders

mood swings
including depression;
changes of the sex
drive (libido)

Nervous system
disorders

nervousness;

Eye disorders

visual disturbances

Gastrointestinal
disorders

nausea, vomiting,
abdominal pain

decreased ability
to metabolize
glucose (glucose
intolerance)

giddiness, dizziness
contact lens
intolerance
diarrhoea,
abdominal
cramps,
flatulence

Hepatobiliary
disorders

jaundice caused
by cholestasis
Frequency of side effects

System Organ
Class

Skin and
subcutaneous
tissue disorders

Reproductive
system and breast
disorders

Common

Uncommon

Rare

Very rare

(may affect up to 1 in
10 people)

(may affect up
to 1 in 100
people)

(may affect up to
1 in 1,000
people)

(may affect up
to 1 in 10,000
people)

acne

rash, yellowishbrown skin
spots
(chloasma)
possibly
persisting,
increased body
and facial hair,
hair loss

red nodules
(Erythema
nodosum)

breast pain, breast
tenderness, breast
hypertrophy, breast
discharge, painful
menstrual bleeding,
changes in the
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Frequency of side effects
System Organ
Class

Common

Uncommon

Rare

Very rare

(may affect up to 1 in
10 people)

(may affect up
to 1 in 100
people)

(may affect up to
1 in 1,000
people)

(may affect up
to 1 in 10,000
people)

blood pressure
increase,
changes in
blood lipid
levels

reduction of the
folic acid levels
in blood

strength of menstrual
bleeding, increased
vaginal discharge,
missed menstrual
bleeding
General disorders

fluid retention in
tissue

Investigations

weight changes
(increase or decrease)
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As regards other severe side effects, such as the formation of blood clots, see 2.2.3 ‘The “Pill” and
vascular disease’, or with respect to hepatic tumors, breast and cervical cancer, see 2.2.4 ‘The “Pill”
and cancer’.
Moreover, the following side effects have been reported in connection with using the ‘Pill’: The
frequency of these reactions cannot be calculated from the reports.
optic neuritis (can cause partial or complete loss of vision),
worsening of varicose veins,
pancreatitis with a currently existing, severe lipid (fat) metabolism disturbance,
gall bladder disorder, including gall stones,
a blood disorder resulting in kidney damage (haemolytic-uremic syndrome),
herpes, which can occur during pregnancy (Herpes gestationis),
a kind of deafness (otosclerosis),
deterioration of lupus, an immune disorder,
deterioration of a blood disorder called porphyria,
deterioration of body movement diseases called “chorea”,
deterioration of depression,
deterioration of chronic inflammatory bowel disease (Crohn's disease and ulcerative colitis).
If you get any side effects, talk to your doctor, health care provider or pharmacist. This includes any
possible side effects not listed in this leaflet.
5.

HOW TO STORE ZINNIA F

Keep this medicine out of the sight and reach of children.
Store below 30oC. Protect from light.
Do not use this medicine after the expiry date which is stated on the label after {EXP}. The expiry
date refers to the last day of that month.
6.

CONTENTS OF THE PACK AND OTHER INFORMATION

What Zinnia F contains:
The active substances in the active tablets are 30 micrograms of ethinylestradiol and 150 micrograms
of levonorgestrel.
The other ingredients are:
White active tablets (21 per blister)
Core tablet: Lactose monohydrate, magnesium stearate, maize starch, povidone and talc.
Coating: Calcium carbonate, carnauba wax, glycerol, macrogol, povidone, sucrose, talc and titanium
dioxide.
Brown hormone free tablets (7 per blister)
Core tablet: Ferrous fumarate, magnesium stearate, maize starch, methylparaben, polysorbate 80,
propylparaben, sodium starch glycolate and talc.
Coating: Carnauba wax, gum acacia, red oxide of iron, shellac, sodium benzoate, sucrose, talc and
titanium dioxide.
What Zinnia F looks like and contents of the pack:
Zinnia F active tablets are 21 white active tablets and 7 brown hormone free tablets.
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A blister strip of Zinnia F tablets contains 21 white, circular, biconvex, sugar-coated tablets, and 7
brown, circular, biconvex, sugar coated tablets. Zinnia F tablets are provided in clear transparent
PVC/PVdC-Alu blister cards in a carton, containing 1, 3, 6 blister cards of 28 tablets each.
Supplier and Manufacturer
Supplier
Mylan Laboratories Limited
Plot No.564/A/22, Road No.92, Jubilee Hills
Hyderabad, Telangana – 500033, India
Contact Person :
Maitrayee Mukherji
Tel. Number of Contact Person :+91-02241244801
Mobile Number of Contact Person :+9109930461678
E mail address : mmukherji@mylan.in

Manufacturer
Active tablets
Mylan Laboratories Limited
Unit II
1608/1609
G.I.D.C, Sarigam
396155 Valsad
Gujarat, India
Hormone free tablets
Mylan Laboratories Limited
Plot No. 20 & 21, Pharmez
Pharmaceutical Special Economic Zone (SEZ)
Sarkhej, Near Matoda, Village
Ahmedabad, India

For any information about this medicinal product, please contact the supplier.
This leaflet was last approved in May 2015. Section 6 updated in February 2017.
Detailed information on this medicine is available on the World Health Organization (WHO) web site:
http://www.who.int/prequal/
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